NDR2
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
Log-Odds: S Sites / S Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| O00488 | S98 | Sugiyama | ZNF593 ZT86 | THFRSKDHKKRLKQLsVEPysQEEAERAAGMGSYVPPRRLA |
| O60285 | T211 | EPSD|PSP | NUAK1 ARK5 KIAA0537 OMPHK1 | NIKIADFGLSNLYQKDKFLQtFCGSPLYASPEIVNGRPYRG |
| O60814 | S37 | Sugiyama | H2BC12 H2BFT HIRIP1 HIST1H2BK | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| O75385 | S495 | SIGNOR|PSP | ULK1 KIAA0722 | RAsPsPPAHAEHGGVLARKMsLGGGRPYTPSPQVGTIPERP |
| P00338 | S161 | Sugiyama | LDHA PIG19 | DILTYVAWKISGFPKNRVIGsGCNLDsARFRyLMGERLGVH |
| P04075 | S36 | Sugiyama | ALDOA ALDA | LsDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENR |
| P04075 | S39 | Sugiyama | ALDOA ALDA | IAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRRFy |
| P04075 | S46 | Sugiyama | ALDOA ALDA | PGKGILAADEstGsIAKRLQsIGtENtEENRRFyRQLLLtA |
| P04406 | S241 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDDIKKV |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P04792 | S83 | Sugiyama | HSPB1 HSP27 HSP28 | IEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVNH |
| P06899 | S37 | Sugiyama | H2BC11 H2BFR HIST1H2BJ | KAVTKAQKKDGKKRKRSRKEsysIyVyKVLKQVHPDTGISS |
| P07195 | S162 | Sugiyama | LDHB | DILTYVTWKLSGLPKHRVIGsGCNLDsARFRyLMAEKLGIH |
| P07814 | S335 | Sugiyama | EPRS1 EPRS GLNS PARS QARS QPRS PIG32 | PIEKNLQMWEEMKKGsQFGQsCCLRAKIDMSSNNGCMRDPt |
| P07864 | S161 | Sugiyama | LDHC LDH3 LDHX | DILTYIVWKISGLPVTRVIGsGCNLDsARFRYLIGEKLGVH |
| P07900 | S53 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | IINtFySNKEIFLRELIsNssDALDKIRyEsLtDPsKLDsG |
| P07900 | Y284 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | DEEEEKKDGDKKKKKKIKEKyIDQEELNKtKPIWtRNPDDI |
| P08238 | Y276 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | DEEDDsGKDKKKKTKKIKEKyIDQEELNKtKPIWtRNPDDI |
| P0CG47 | S57 | Sugiyama | UBB | PPDQQRLIFAGKQLEDGRtLsDyNIQKEstLHLVLRLRGGM |
| P0CG48 | S57 | Sugiyama | UBC | PPDQQRLIFAGKQLEDGRtLsDyNIQKEstLHLVLRLRGGM |
| P0DPH7 | S48 | Sugiyama | TUBA3C TUBA2 | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| P10412 | S36 | Sugiyama | H1-4 H1F4 HIST1H1E | EKtPVKKKARKsAGAAKRKAsGPPVsELItKAVAASKERsG |
| P10412 | S55 | Sugiyama | H1-4 H1F4 HIST1H1E | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P13639 | S23 | Sugiyama | EEF2 EF2 | NFtVDQIRAIMDKKANIRNMsVIAHVDHGKStLtDsLVCKA |
| P13639 | S593 | Sugiyama | EEF2 EF2 | SDPVVsyREtVsEEsNVLCLsKsPNKHNRLyMKARPFPDGL |
| P14314 | S126 | Sugiyama | PRKCSH G19P1 | yNsGVICENtCKEKGRKEREsLQQMAEVtREGFRLKKILIE |
| P15531 | S120 | Sugiyama | NME1 NDPKA NM23 | KPGtIRGDFCIQVGRNIIHGsDsVEsAEKEIGLWFHPEELV |
| P16402 | S37 | Sugiyama | H1-3 H1F3 HIST1H1D | KtPVKKKAKKAGATAGKRKAsGPPVsELItKAVAASKERsG |
| P16402 | S56 | Sugiyama | H1-3 H1F3 HIST1H1D | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P16403 | S55 | Sugiyama | H1-2 H1F2 HIST1H1C | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P22059 | S190 | Sugiyama | OSBP OSBP1 | QRWVTALELAKAKAVKMLAEsDEsGDEEsVsQtDKTELQNT |
| P22059 | S193 | Sugiyama | OSBP OSBP1 | VTALELAKAKAVKMLAEsDEsGDEEsVsQtDKTELQNTLRT |
| P22090 | S204 | Sugiyama | RPS4Y1 RPS4Y PRO2646 | IGGANLGRVGVITNRERHPGsFDVVHVKDANGNSFATRLSN |
| P23527 | S37 | Sugiyama | H2BC17 H2BFH H2BFN HIST1H2BO | KAVTKAQKKDGKKRKRSRKEsysIyVyKVLKQVHPDTGISS |
| P23588 | S122 | Sugiyama | EIF4B | NLPyDVTEESIKEFFRGLNIsAVRLPREPsNPERLKGFGyA |
| P26038 | S576 | Sugiyama | MSN | YKtLRQIRQGNTKQRIDEFEsM___________________ |
| P26038 | T526 | Sugiyama | MSN | EERTTEAEKNERVQKHLKALtsELANARDEsKKTANDMIHA |
| P30086 | S54 | Sugiyama | PEBP1 PBP PEBP | VDELGKVLtPtQVKNRPtsIsWDGLDsGKLytLVLtDPDAP |
| P31948 | S16 | Sugiyama | STIP1 | _____MEQVNELKEKGNKALsVGNIDDALQCysEAIKLDPH |
| P33316 | S120 | Sugiyama | DUT | PsKRARPAEVGGMQLRFARLsEHAtAPTRGsARAAGYDLYS |
| P33316 | S164 | Sugiyama | DUT | YTIPPMEKAVVKTDIQIALPsGCyGRVAPRSGLAAKHFIDV |
| P33778 | S37 | Sugiyama | H2BC3 H2BFF HIST1H2BB | KAITKAQKKDGKKRKRsRKEsysIyVyKVLKQVHPDTGISS |
| P35637 | S360 | Sugiyama | FUS TLS | sFDDPPsAKAAIDWFDGKEFsGNPIKVsFATRRADFNRGGG |
| P36578 | S87 | Sugiyama | RPL4 RPL1 | WGtGRAVARIPRVRGGGtHRsGQGAFGNMCRGGRMFAPTKT |
| P37802 | S163 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | LFsGDPNWFPKKSKENPRNFsDNQLQEGKNVIGLQMGtNRG |
| P37802 | S185 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | NQLQEGKNVIGLQMGtNRGAsQAGMtGyGMPRQIL______ |
| P38646 | S89 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | VMEGKQAKVLENAEGARttPsVVAFtADGERLVGMPAKRQA |
| P39023 | S13 | Sugiyama | RPL3 OK/SW-cl.32 | ________MSHRKFSAPRHGsLGFLPRKRSSRHRGKVKSFP |
| P43034 | S152 | Sugiyama | PAFAH1B1 LIS1 MDCR MDS PAFAHA | IKVWDyEtGDFERtLKGHtDsVQDIsFDHsGKLLASCSADM |
| P43243 | S188 | Sugiyama | MATR3 KIAA0723 | EPPyRVPRDDWEEKRHFRRDsFDDRGPsLNPVLDyDHGsRs |
| P46776 | S68 | Sugiyama | RPL27A | yHPGyFGKVGMKHYHLKRNQsFCPtVNLDKLWtLVsEQtRV |
| P46777 | S224 | Sugiyama | RPL5 MSTP030 | VADyMRyLMEEDEDAyKKQFsQyIKNsVtPDMMEEMyKKAH |
| P46937 | S109 | Sugiyama | YAP1 YAP65 | RKLPDsFFKPPEPKsHsRQAstDAGtAGALtPQHVRAHssP |
| P46937 | S127 | EPSD|PSP | YAP1 YAP65 | QAstDAGtAGALtPQHVRAHssPAsLQLGAVsPGtLtPtGV |
| P46937 | T114 | Sugiyama | YAP1 YAP65 | sFFKPPEPKsHsRQAstDAGtAGALtPQHVRAHssPAsLQL |
| P47712 | S727 | Sugiyama | PLA2G4A CPLA2 PLA2G4 | VIKEAMVESIEyRRQNPsRCsVsLsNVEARRFFNKEFLSKP |
| P49321 | S659 | Sugiyama | NASP | IEELKELLPEIREKIEDAKEsQRsGNVAELALKATLVEsst |
| P50990 | S23 | Sugiyama | CCT8 C21orf112 CCTQ KIAA0002 | LHVPKAPGFAQMLKEGAKHFsGLEEAVyRNIQACKELAQTT |
| P50991 | T50 | Sugiyama | CCT4 CCTD SRB | PAQIRFsNISAAKAVADAIRtsLGPKGMDKMIQDGKGDVtI |
| P51116 | S601 | Sugiyama | FXR2 FMR1L2 | RPQRRNRSRRRRNRGNRtDGsIsGDRQPVtVADyIsRAEsQ |
| P51532 | S1380 | Sugiyama | SMARCA4 BAF190A BRG1 SNF2B SNF2L4 | EEEEEKMFGRGSRHRKEVDYsDsLTEKQWLKAIEEGtLEEI |
| P51532 | S1382 | Sugiyama | SMARCA4 BAF190A BRG1 SNF2B SNF2L4 | EEEKMFGRGSRHRKEVDYsDsLTEKQWLKAIEEGtLEEIEE |
| P51858 | S83 | Sugiyama | HDGF HMG1L2 | LFPyEEsKEKFGKPNKRKGFsEGLWEIENNPtVKASGYQSs |
| P52209 | S126 | Sugiyama | PGD PGDH | YRDTTRRCRDLKAKGILFVGsGVsGGEEGARyGPSLMPGGN |
| P53396 | S455 | Sugiyama | ACLY | ANFLLNAsGststPAPsRtAsFsEsRADEVAPAKKAKPAMP |
| P57053 | S37 | Sugiyama | H2BC12L H2BFS H2BS1 | KAVTKAQKKDGRKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| P57721 | S82 | Sugiyama | PCBP3 PCBP3-OT1 PCBP3OT | GKKGETVKKMREESGARINIsEGNCPERIVTITGPTDAIFK |
| P58876 | S37 | Sugiyama | H2BC5 H2BFB HIRIP2 HIST1H2BD | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| P60174 | S212 | Sugiyama | TPI1 TPI | WLKsNVsDAVAQstRIIyGGsVtGAtCKELASQPDVDGFLV |
| P60709 | S52 | Sugiyama | ACTB | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62258 | S148 | Sugiyama | YWHAE | YHRyLAEFAtGNDRKEAAENsLVAyKAAsDIAMtELPPTHP |
| P62263 | S137 | Sugiyama | RPS14 PRO2640 | RALARSGMKIGRIEDVtPIPsDstRRKGGRRGRRL______ |
| P62273 | S9 | Sugiyama | RPS29 | ____________MGHQQLyWsHPRKFGQGSRSCRVCSNRHG |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62277 | S14 | Sugiyama | RPS13 | _______MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDDVK |
| P62701 | S204 | Sugiyama | RPS4X CCG2 RPS4 SCAR | tGGANLGRIGVITNRERHPGsFDVVHVKDANGNSFATRLsN |
| P62736 | S54 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P62807 | S37 | Sugiyama | H2BC4 H2BFL HIST1H2BC; H2BC6 H2BFH HIST1H2BE; H2BC7 H2BFG HIST1H2BF; H2BC8 H2BFA HIST1H2BG; H2BC10 H2BFK HIST1H2BI | KAVTKAQKKDGKKRKRsRKEsysVyVyKVLKQVHPDTGIss |
| P62899 | S15 | Sugiyama | RPL31 | ______MAPAKKGGEKKKGRsAINEVVtREytINIHKRIHG |
| P62917 | S130 | Sugiyama | RPL8 | GTIVCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKL |
| P62917 | T146 | Sugiyama | RPL8 | LARAsGNyAtVIsHNPEtKKtRVKLPSGSKKVISSANRAVV |
| P62917 | Y133 | Sugiyama | RPL8 | VCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSG |
| P62937 | S51 | Sugiyama | PPIA CYPA | KtAENFRALSTGEKGFGYKGsCFHRIIPGFMCQGGDFtRHN |
| P62979 | S123 | Sugiyama | RPS27A UBA80 UBCEP1 | LKYYKVDENGKIsRLRRECPsDECGAGVFMAsHFDRHyCGK |
| P62979 | S57 | Sugiyama | RPS27A UBA80 UBCEP1 | PPDQQRLIFAGKQLEDGRtLsDyNIQKEstLHLVLRLRGGA |
| P62987 | S57 | Sugiyama | UBA52 UBCEP2 | PPDQQRLIFAGKQLEDGRtLsDyNIQKEstLHLVLRLRGGI |
| P63261 | S52 | Sugiyama | ACTG1 ACTG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P63267 | S53 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P67809 | S102 | Sugiyama | YBX1 NSEP1 YB1 | EDVFVHQtAIKKNNPRKyLRsVGDGEtVEFDVVEGEKGAEA |
| P67809 | S209 | Sugiyama | YBX1 NSEP1 YB1 | RRRRFPPyyMRRPYGRRPQysNPPVQGEVMEGADNQGAGEQ |
| P67809 | Y196 | Sugiyama | YBX1 NSEP1 YB1 | sAPEGQAQQRRPyRRRRFPPyyMRRPYGRRPQysNPPVQGE |
| P67809 | Y197 | Sugiyama | YBX1 NSEP1 YB1 | APEGQAQQRRPyRRRRFPPyyMRRPYGRRPQysNPPVQGEV |
| P67809 | Y99 | Sugiyama | YBX1 NSEP1 YB1 | DtKEDVFVHQtAIKKNNPRKyLRsVGDGEtVEFDVVEGEKG |
| P68032 | S54 | Sugiyama | ACTC1 ACTC | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68133 | S54 | Sugiyama | ACTA1 ACTA | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68363 | S48 | Sugiyama | TUBA1B | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| P83731 | S38 | Sugiyama | RPL24 | GRRYARTDGKVFQFLNAKCEsAFLSKRNPRQINWtVLyRRK |
| Q01105 | S161 | Sugiyama | SET | FDENPyFENKVLSKEFHLNEsGDPssKstEIKWKSGKDLTK |
| Q07021 | S106 | Sugiyama | C1QBP GC1QBP HABP1 SF2P32 | LsDEIKEERKIQKHKTLPKMsGGWELELNGTEAKLVRKVAG |
| Q08945 | S657 | Sugiyama | SSRP1 FACT80 | MEKKSTPSRGsSSKSsSRQLsEsFKSKEFVssDEsssGENK |
| Q13247 | S297 | Sugiyama | SRSF6 SFRS6 SRP55 | RSRSPKENGKGDIKsKSRsRsQsRsNsPLPVPPsKARsVsP |
| Q13247 | S301 | Sugiyama | SRSF6 SFRS6 SRP55 | PKENGKGDIKsKSRsRsQsRsNsPLPVPPsKARsVsPPPKR |
| Q13283 | S67 | Sugiyama | G3BP1 G3BP | sNGKPADAVyGQKEIHRKVMsQNFtNCHTKIRHVDAHATLN |
| Q13442 | S19 | Sugiyama | PDAP1 HASPP28 | __MPKGGRKGGHKGRARQytsPEEIDAQLQAEKQKAREEEE |
| Q13442 | T18 | Sugiyama | PDAP1 HASPP28 | ___MPKGGRKGGHKGRARQytsPEEIDAQLQAEKQKAREEE |
| Q13442 | Y17 | Sugiyama | PDAP1 HASPP28 | ____MPKGGRKGGHKGRARQytsPEEIDAQLQAEKQKAREE |
| Q14103 | S271 | Sugiyama | HNRNPD AUF1 HNRPD | KCEIKVAMSKEQyQQQQQWGsRGGFAGRARGRGGGPSQNWN |
| Q14152 | S584 | Sugiyama | EIF3A EIF3S10 KIAA0139 | EHQRILARRQtIEERKERLEsLNIQREKEELEQREAELQKV |
| Q14432 | T311 | Sugiyama | PDE3A | RsssVVsAEMSGCSSKSHRRtsLPCIPREQLMGHSEWDHKR |
| Q14568 | S53 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | IINTFYSNKEIFLRELIsNssDALDKIWYESLTDPSKLDSG |
| Q14568 | Y283 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | sDEEEEKKDGDKKKKKTKEKyIDQEELNKTKPIWTRNPDDI |
| Q14653 | S396 | PSP | IRF3 | VEMARVGGAssLENtVDLHIsNsHPLsLtsDQYKAYLQDLV |
| Q14738 | S573 | Sugiyama | PPP2R5D | TEAVQMLKDIKKEKVLLRRKsELPQDVyTIKALEAHKRAEE |
| Q14978 | S686 | Sugiyama | NOLC1 KIAA0035 NS5ATP13 | KGKSFRHEKTKKKRGsYRGGsIsVQVNsIKFDsE_______ |
| Q15293 | Y115 | Sugiyama | RCN1 RCN | GDGFVttEELKtWIKRVQKRyIFDNVAKVWKDYDRDKDDKI |
| Q15365 | S50 | Sugiyama | PCBP1 | GKKGESVKRIREEsGARINIsEGNCPERIItLTGPTNAIFK |
| Q15366 | S50 | Sugiyama | PCBP2 | GKKGESVKKMREESGARINIsEGNCPERIITLAGPTNAIFK |
| Q16778 | S37 | Sugiyama | H2BC21 H2BFQ HIST2H2BE | KAVTKAQKKDGKKRKRSRKEsysIyVyKVLKQVHPDTGIss |
| Q58FF8 | Y198 | Sugiyama | HSP90AB2P HSP90BB | DEEDDsGKDKKKKTKKIKEKyIDQEELNKTKPIWTRNTEDI |
| Q5QNW6 | S37 | Sugiyama | H2BC18 HIST2H2BF | KAVTKVQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q5T5C0 | S692 | Sugiyama | STXBP5 LLGL3 | YGSNDPYRREPRSPRKsRQPsGAGLCDIsEGtVVPEDRCKS |
| Q6DD87 | S104 | Sugiyama | ZNF787 | HQRTHtGERPNACADCGKTFsQSSHLVQHRRIHtGEKPYAC |
| Q6DN03 | S37 | Sugiyama | H2BC20P HIST2H2BC | KAVTKAQKKDGKKRKRSRKEsysIyVyKVLKRVHPDTGIWC |
| Q6DRA6 | S37 | Sugiyama | H2BC19P HIST2H2BD | KAVTKAQKKDGKKRKRSRKEsysIyVyKVLKRVHPDTGIWC |
| Q6P158 | S70 | Sugiyama | DHX57 | NRKAssRIWDDGDDFCIFSEsRRPsRPsNSNISKGESRPKW |
| Q6PEY2 | S48 | Sugiyama | TUBA3E | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| Q6ZMR3 | S161 | Sugiyama | LDHAL6A LDHL2 | DILTYVAWKLSGFPKNRVIGsGCNLDsARFRYFIGQRLGIH |
| Q6ZVN8 | T290 | Sugiyama | HJV HFE2 RGMC | PGNHVEIQAAYIGTTIIIRQtAGQLSFSIKVAEDVAMAFSA |
| Q71U36 | S48 | Sugiyama | TUBA1A TUBA3 | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| Q7KZ85 | S1668 | Sugiyama | SUPT6H KIAA0162 SPT6H | QAQPQPSSSSRQRQQQPKsNsHAAIDWGKMAEQWLQEKEAE |
| Q7Z4V5 | S454 | Sugiyama | HDGFL2 HDGF2 HDGFRP2 HRP2 UNQ785/PRO1604 | VRPEEKQQAKPVKVERTRKRsEGFsMDRKVEKKKEPSVEEK |
| Q86VQ1 | S223 | Sugiyama | GLCCI1 | QTPsCWAEEGAEKRSHQRsAsWGsADQLKEQIAKLRQQLQR |
| Q8N257 | S37 | Sugiyama | H2BC26 H2BU1 HIST3H2BB | KAVTKAQKKDGKKRKRGRKEsysIyVyKVLKQVHPDTGIss |
| Q8NFD5 | S1744 | Sugiyama | ARID1B BAF250B DAN15 KIAA1235 OSA2 | ALDTINILLYDDSTVATFNLsQLSGFLELLVEYFRKCLIDI |
| Q8TAM6 | S280 | Sugiyama | ERMN KIAA1189 | TISYRKIRKGNTKQRIDEFEsMMHL________________ |
| Q92597 | S332 | Sugiyama | NDRG1 CAP43 DRG1 RTP | MGYMPsAsMtRLMRsRtAsGssVtsLDGtRsRsHtSEGTRs |
| Q93079 | S37 | Sugiyama | H2BC9 H2BFJ HIST1H2BH | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q96QF0 | S288 | EPSD|PSP | RAB3IP RABIN8 | tQEPLPGGKTPFKKGHTRNKstssAMsGsHQDLSVIQPIVK |
| Q99570 | S853 | Sugiyama | PIK3R4 VPS15 | LVKTKQEPDDKRARKHVKQDsNVNEEWKsMFGsLDPPNMPQ |
| Q99877 | S37 | Sugiyama | H2BC15 H2BFD HIST1H2BN | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q99879 | S37 | Sugiyama | H2BC14 H2BFE HIST1H2BM | KAINKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q99880 | S37 | Sugiyama | H2BC13 H2BFC HIST1H2BL | KAVTKAQKKDGKKRKRSRKEsysVyVyKVLKQVHPDTGIss |
| Q9BQE3 | S48 | Sugiyama | TUBA1C TUBA6 | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| Q9BTU6 | S462 | Sugiyama | PI4K2A | HLVQMPPVIVETARSHQRsssEsyTQsFQSRKPFFSWW___ |
| Q9GZL7 | S206 | Sugiyama | WDR12 | RGHAGSVDSIAVDGSGTKFCsGSWDKMLKIWStVPtDEEDE |
| Q9H4A3 | T2245 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | TVNSQAAQAQPPAMTSSRKGtFtDDLHKLVDNWARDAMNLS |
| Q9H4A3 | T2247 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | NSQAAQAQPPAMTSSRKGtFtDDLHKLVDNWARDAMNLSGR |
| Q9NWS0 | S173 | Sugiyama | PIH1D1 NOP17 | KYNLQLNPEWRMMKNRPFMGsIsQQNIRSEQRPRIQELGDL |
| Q9P0L0 | S166 | Sugiyama | VAPA VAP33 | KAVPLNASKQDGPMPKPHsVsLNDtEtRKLMEECKRLQGEM |
| Q9UGV2 | T332 | Sugiyama | NDRG3 | GMGYIPSASMTRLARsRtHstsssLGsGEsPFsRsVtsNQs |
| Q9UI15 | S185 | Sugiyama | TAGLN3 NP25 | EQLRQGQNVIGLQMGSNKGAsQAGMtGyGMPRQIM______ |
| Q9UPQ0 | S201 | Sugiyama | LIMCH1 KIAA1102 | DCWDsERsDsLsPPRHGRDDsFDsLDsFGsRsRQtPsPDVV |
| Q9UPT8 | S137 | Sugiyama | ZC3H4 C19orf7 KIAA1064 | RSKKRRKSKHKRHAsSSDDFsDFsDDsDFsPSEKGHRKyRE |
| Q9UQ35 | S2692 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | ERRSRSPRKPIDsLRDsRsLsysPVERRRPsPQPsPRDQQS |
| Q9UQ35 | S854 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | sHSsssPHPKVKsGtPPRQGsItsPQANEQsVtPQRRsCFE |
| Q9Y2B0 | S63 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | AQVDPKKTIQMGsFRINPDGsQsVVEVPyARsEAHLtELLE |
| Q9Y2B0 | S65 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | VDPKKTIQMGsFRINPDGsQsVVEVPyARsEAHLtELLEEI |
| Q9Y2H1 | S282 | GPS6|SIGNOR|ELM|EPSD|PSP | STK38L KIAA0965 NDR2 | NMNsKRKAETWKKNRRQLAystVGtPDyIAPEVFMQTGYNK |
| Q9Y2H1 | S372 | Sugiyama | STK38L KIAA0965 NDR2 | EKAKDLILRFCIDSENRIGNsGVEEIKGHPFFEGVDWEHIR |
| Q9Y2H1 | S454 | Sugiyama | STK38L KIAA0965 NDR2 | KDWVFLNytYKRFEGLtQRGsIPTYMKAGKL__________ |
| Q9Y2H1 | Y441 | Sugiyama | STK38L KIAA0965 NDR2 | QPVPNTTEPDYKSKDWVFLNytYKRFEGLtQRGsIPTYMKA |
| Q9Y3S1 | T2157 | Sugiyama | WNK2 KIAA1760 PRKWNK2 SDCCAG43 P/OKcl.13 | GPQPALHVQAQVNNSNNKKGtFtDDLHKLVDEWTSKTVGAA |
| Q9Y3S1 | T2159 | Sugiyama | WNK2 KIAA1760 PRKWNK2 SDCCAG43 P/OKcl.13 | QPALHVQAQVNNSNNKKGtFtDDLHKLVDEWTSKTVGAAQL |
| Q9Y3U8 | S91 | Sugiyama | RPL36 | KFIKKRVGTHIRAKRKREELsNVLAAMRKAAAKKD______ |
| Q9Y5U2 | S86 | Sugiyama | TSSC4 | PSPPSGLLPATVQPFHLRGMssTFSQRsRDIFDCLEGAARR |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 0.000001 | 5.975 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 0.000024 | 4.625 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 0.000026 | 4.581 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 0.000028 | 4.558 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 0.000037 | 4.430 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 0.000049 | 4.309 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 0.000064 | 4.197 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 0.000066 | 4.183 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 0.000072 | 4.141 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 0.000073 | 4.134 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 0.000120 | 3.920 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 0.000136 | 3.866 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 0.000153 | 3.814 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 0.000174 | 3.760 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 0.000226 | 3.646 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 0.000293 | 3.533 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 0.000290 | 3.538 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 0.000448 | 3.349 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 0.000472 | 3.326 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 0.000501 | 3.301 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 0.000612 | 3.213 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 0.000666 | 3.177 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 0.000747 | 3.127 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 0.000746 | 3.127 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 0.000885 | 3.053 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 0.001012 | 2.995 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 0.001117 | 2.952 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 0.001150 | 2.939 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 0.001174 | 2.930 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 0.001306 | 2.884 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 0.001934 | 2.714 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 0.001996 | 2.700 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 0.002013 | 2.696 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 0.002255 | 2.647 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 0.002290 | 2.640 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 0.002456 | 2.610 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 0.002620 | 2.582 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 0.002742 | 2.562 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 0.003227 | 2.491 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 0.003332 | 2.477 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 0.003582 | 2.446 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 0.003751 | 2.426 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 0.003825 | 2.417 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 0.003845 | 2.415 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 0.004298 | 2.367 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 0.004178 | 2.379 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 0.004532 | 2.344 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 0.005343 | 2.272 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 0.005299 | 2.276 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 0.005299 | 2.276 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 0.005299 | 2.276 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 0.005299 | 2.276 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 0.005299 | 2.276 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 0.005342 | 2.272 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 0.005547 | 2.256 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 0.005382 | 2.269 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 0.005104 | 2.292 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 0.004702 | 2.328 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 0.005939 | 2.226 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 0.005964 | 2.224 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 0.006574 | 2.182 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 0.006968 | 2.157 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 0.006926 | 2.160 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 0.007221 | 2.141 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 0.007221 | 2.141 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 0.007150 | 2.146 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 0.007954 | 2.099 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 0.008825 | 2.054 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 0.008676 | 2.062 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 0.009043 | 2.044 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 0.010345 | 1.985 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 0.010423 | 1.982 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 0.010423 | 1.982 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 0.010087 | 1.996 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 0.010326 | 1.986 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 0.010510 | 1.978 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 0.009746 | 2.011 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 0.011351 | 1.945 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 0.011736 | 1.930 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 0.012333 | 1.909 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 0.012373 | 1.908 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 0.012655 | 1.898 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 0.012583 | 1.900 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 0.013432 | 1.872 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 0.014016 | 1.853 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 0.014521 | 1.838 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 0.015663 | 1.805 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 0.016212 | 1.790 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 0.017418 | 1.759 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 0.017418 | 1.759 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 0.017418 | 1.759 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 0.018852 | 1.725 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 0.018852 | 1.725 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 0.018852 | 1.725 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 0.018852 | 1.725 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 0.018852 | 1.725 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 0.018808 | 1.726 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 0.020025 | 1.698 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 0.020994 | 1.678 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 0.020994 | 1.678 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 0.021511 | 1.667 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 0.022188 | 1.654 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 0.022188 | 1.654 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 0.022949 | 1.639 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 0.022949 | 1.639 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 0.022949 | 1.639 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 0.022949 | 1.639 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 0.021959 | 1.658 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 0.023325 | 1.632 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 0.024096 | 1.618 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 0.024096 | 1.618 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 0.026377 | 1.579 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 0.025537 | 1.593 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 0.025537 | 1.593 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 0.027145 | 1.566 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 0.027329 | 1.563 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 0.027597 | 1.559 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 0.027597 | 1.559 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 0.027775 | 1.556 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 0.028691 | 1.542 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 0.030151 | 1.521 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 0.030151 | 1.521 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 0.030151 | 1.521 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 0.034183 | 1.466 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 0.032426 | 1.489 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 0.034210 | 1.466 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 0.034286 | 1.465 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 0.035106 | 1.455 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 0.035106 | 1.455 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 0.035106 | 1.455 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 0.037185 | 1.430 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 0.037617 | 1.425 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 0.037864 | 1.422 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 0.039638 | 1.402 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 0.039804 | 1.400 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 0.042333 | 1.373 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 0.039804 | 1.400 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 0.042438 | 1.372 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 0.042438 | 1.372 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 0.043692 | 1.360 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 0.043692 | 1.360 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 0.043692 | 1.360 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 0.048415 | 1.315 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 0.048415 | 1.315 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 0.048933 | 1.310 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 0.048933 | 1.310 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 0.045962 | 1.338 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 0.045962 | 1.338 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 0.045788 | 1.339 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 0.046586 | 1.332 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 0.048159 | 1.317 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 0.048986 | 1.310 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 0.048986 | 1.310 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 0.044269 | 1.354 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 0.048659 | 1.313 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 0.050438 | 1.297 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 0.050438 | 1.297 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 0.050617 | 1.296 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 0.052111 | 1.283 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 0.052111 | 1.283 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 0.052111 | 1.283 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 0.052127 | 1.283 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 0.052698 | 1.278 | 0 | 0 |
| M Phase | R-HSA-68886 | 0.052900 | 1.277 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 0.053056 | 1.275 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 0.060023 | 1.222 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 0.054360 | 1.265 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 0.054687 | 1.262 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 0.054687 | 1.262 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 0.058906 | 1.230 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 0.054430 | 1.264 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 0.059754 | 1.224 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 0.060078 | 1.221 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 0.060367 | 1.219 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 0.060802 | 1.216 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 0.060802 | 1.216 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 0.060802 | 1.216 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 0.060802 | 1.216 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 0.060844 | 1.216 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 0.060896 | 1.215 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 0.061048 | 1.214 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 0.063787 | 1.195 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 0.065691 | 1.182 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 0.065892 | 1.181 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 0.065892 | 1.181 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 0.073344 | 1.135 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 0.070691 | 1.151 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 0.070691 | 1.151 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 0.075182 | 1.124 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 0.075909 | 1.120 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 0.072057 | 1.142 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 0.067970 | 1.168 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 0.075574 | 1.122 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 0.072057 | 1.142 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 0.070835 | 1.150 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 0.073344 | 1.135 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 0.068230 | 1.166 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 0.077386 | 1.111 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 0.081285 | 1.090 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 0.082555 | 1.083 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 0.082667 | 1.083 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 0.098794 | 1.005 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 0.187833 | 0.726 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 0.187833 | 0.726 | 0 | 0 |
| Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI) | R-HSA-9036092 | 0.187833 | 0.726 | 0 | 0 |
| Defective SLC2A10 causes arterial tortuosity syndrome (ATS) | R-HSA-5619068 | 0.187833 | 0.726 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 0.187833 | 0.726 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 0.187833 | 0.726 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 0.096333 | 1.016 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 0.096333 | 1.016 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 0.129878 | 0.886 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 0.129878 | 0.886 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 0.129878 | 0.886 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 0.129878 | 0.886 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 0.268079 | 0.572 | 0 | 0 |
| Intestinal infectious diseases | R-HSA-8942233 | 0.268079 | 0.572 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 0.268079 | 0.572 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 0.087781 | 1.057 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 0.087781 | 1.057 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 0.165617 | 0.781 | 0 | 0 |
| IRS activation | R-HSA-74713 | 0.165617 | 0.781 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 0.108581 | 0.964 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 0.108581 | 0.964 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 0.108581 | 0.964 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 0.108581 | 0.964 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 0.087824 | 1.056 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 0.131070 | 0.882 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 0.131070 | 0.882 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 0.202790 | 0.693 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 0.202790 | 0.693 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 0.340401 | 0.468 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 0.340401 | 0.468 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 0.340401 | 0.468 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 0.340401 | 0.468 | 0 | 0 |
| Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages) | R-HSA-5619049 | 0.340401 | 0.468 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 0.340401 | 0.468 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 0.340401 | 0.468 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 0.340401 | 0.468 | 0 | 0 |
| HHAT G278V doesn't palmitoylate Hh-Np | R-HSA-5658034 | 0.340401 | 0.468 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 0.340401 | 0.468 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 0.340401 | 0.468 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 0.340401 | 0.468 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 0.340401 | 0.468 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 0.340401 | 0.468 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 0.103568 | 0.985 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 0.103568 | 0.985 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 0.155018 | 0.810 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 0.155018 | 0.810 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 0.120497 | 0.919 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 0.240766 | 0.618 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 0.094776 | 1.023 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 0.180195 | 0.744 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 0.108196 | 0.966 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 0.096364 | 1.016 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 0.157553 | 0.803 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 0.206374 | 0.685 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 0.206374 | 0.685 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 0.279023 | 0.554 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 0.279023 | 0.554 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 0.279023 | 0.554 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 0.279023 | 0.554 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 0.279023 | 0.554 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 0.279023 | 0.554 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 0.279023 | 0.554 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 0.279023 | 0.554 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 0.405581 | 0.392 | 0 | 0 |
| Signaling by plasma membrane FGFR1 fusions | R-HSA-8853336 | 0.405581 | 0.392 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 0.405581 | 0.392 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 0.405581 | 0.392 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 0.405581 | 0.392 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 0.233336 | 0.632 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 0.233336 | 0.632 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 0.233336 | 0.632 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 0.233336 | 0.632 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 0.233336 | 0.632 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 0.233336 | 0.632 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 0.233336 | 0.632 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 0.198199 | 0.703 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 0.317135 | 0.499 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 0.260874 | 0.584 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 0.260874 | 0.584 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 0.219602 | 0.658 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 0.219602 | 0.658 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 0.139778 | 0.855 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 0.106395 | 0.973 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 0.088797 | 1.052 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 0.176135 | 0.754 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 0.176135 | 0.754 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 0.354758 | 0.450 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 0.464323 | 0.333 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 0.464323 | 0.333 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 0.464323 | 0.333 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 0.464323 | 0.333 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 0.464323 | 0.333 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 0.464323 | 0.333 | 0 | 0 |
| Defective CP causes aceruloplasminemia (ACERULOP) | R-HSA-5619060 | 0.464323 | 0.333 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 0.191487 | 0.718 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 0.134861 | 0.870 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 0.264028 | 0.578 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 0.178656 | 0.748 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 0.316916 | 0.499 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 0.316916 | 0.499 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 0.316916 | 0.499 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 0.316916 | 0.499 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 0.242510 | 0.615 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 0.261783 | 0.582 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 0.093285 | 1.030 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 0.345076 | 0.462 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 0.087436 | 1.058 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 0.204883 | 0.688 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 0.281392 | 0.551 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 0.281392 | 0.551 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 0.103183 | 0.986 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 0.103183 | 0.986 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 0.122291 | 0.913 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 0.251910 | 0.599 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 0.251910 | 0.599 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 0.373126 | 0.428 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 0.427494 | 0.369 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 0.427494 | 0.369 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 0.427494 | 0.369 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 0.427494 | 0.369 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 0.427494 | 0.369 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 0.427494 | 0.369 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 0.427494 | 0.369 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 0.517263 | 0.286 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 0.517263 | 0.286 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 0.517263 | 0.286 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 0.210218 | 0.677 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 0.210218 | 0.677 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 0.165899 | 0.780 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 0.292305 | 0.534 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 0.356472 | 0.448 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 0.096358 | 1.016 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 0.196785 | 0.706 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 0.400933 | 0.397 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 0.246245 | 0.609 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 0.210906 | 0.676 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 0.462225 | 0.335 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 0.462225 | 0.335 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 0.462225 | 0.335 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 0.205503 | 0.687 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 0.236946 | 0.625 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 0.304559 | 0.516 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 0.428381 | 0.368 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 0.332329 | 0.478 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 0.332329 | 0.478 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 0.332329 | 0.478 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 0.332329 | 0.478 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 0.319660 | 0.495 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 0.334898 | 0.475 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 0.350245 | 0.456 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 0.402567 | 0.395 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 0.495686 | 0.305 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 0.495686 | 0.305 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 0.495686 | 0.305 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 0.495686 | 0.305 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 0.564974 | 0.248 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 0.564974 | 0.248 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 0.564974 | 0.248 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 0.564974 | 0.248 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 0.564974 | 0.248 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 0.564974 | 0.248 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 0.564974 | 0.248 | 0 | 0 |
| Defective CSF2RA causes SMDP4 | R-HSA-5688890 | 0.564974 | 0.248 | 0 | 0 |
| Defective CSF2RB causes SMDP5 | R-HSA-5688849 | 0.564974 | 0.248 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 0.564974 | 0.248 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 0.337179 | 0.472 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 0.303146 | 0.518 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 0.422803 | 0.374 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 0.364299 | 0.439 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 0.419298 | 0.377 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 0.412217 | 0.385 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 0.527789 | 0.278 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 0.527789 | 0.278 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 0.462840 | 0.335 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 0.507608 | 0.294 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 0.493533 | 0.307 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 0.493533 | 0.307 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 0.493533 | 0.307 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 0.428219 | 0.368 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 0.515297 | 0.288 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 0.558474 | 0.253 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 0.558474 | 0.253 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 0.558474 | 0.253 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 0.557107 | 0.254 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 0.557107 | 0.254 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 0.587710 | 0.231 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 0.587710 | 0.231 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 0.587710 | 0.231 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 0.587710 | 0.231 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 0.587710 | 0.231 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 0.587710 | 0.231 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 0.587710 | 0.231 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 0.580705 | 0.236 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 0.576625 | 0.239 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 0.576625 | 0.239 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 0.577359 | 0.239 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 0.275996 | 0.559 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 0.360279 | 0.443 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 0.292305 | 0.534 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 0.223611 | 0.651 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 0.507608 | 0.294 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 0.507608 | 0.294 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 0.191487 | 0.718 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 0.386996 | 0.412 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 0.386996 | 0.412 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 0.400933 | 0.397 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 0.400933 | 0.397 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 0.086992 | 1.061 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 0.168905 | 0.772 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 0.094776 | 1.023 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 0.386996 | 0.412 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 0.097734 | 1.010 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 0.264028 | 0.578 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 0.165968 | 0.780 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 0.515297 | 0.288 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 0.328149 | 0.484 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 0.123860 | 0.907 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 0.264028 | 0.578 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 0.545923 | 0.263 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 0.282346 | 0.549 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 0.221518 | 0.655 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 0.220432 | 0.657 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 0.095247 | 1.021 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 0.540023 | 0.268 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 0.329753 | 0.482 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 0.155018 | 0.810 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 0.176135 | 0.754 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 0.310446 | 0.508 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 0.242507 | 0.615 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 0.473444 | 0.325 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 0.171400 | 0.766 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 0.280244 | 0.552 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 0.260874 | 0.584 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 0.423834 | 0.373 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 0.391616 | 0.407 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 0.240296 | 0.619 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 0.251910 | 0.599 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 0.312090 | 0.506 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 0.363135 | 0.440 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 0.176135 | 0.754 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 0.136363 | 0.865 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 0.373126 | 0.428 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 0.258715 | 0.587 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 0.266357 | 0.575 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 0.317135 | 0.499 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 0.354758 | 0.450 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 0.165217 | 0.782 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 0.391616 | 0.407 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 0.141507 | 0.849 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 0.427494 | 0.369 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 0.216801 | 0.664 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 0.382784 | 0.417 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 0.473952 | 0.324 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 0.577774 | 0.238 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 0.258715 | 0.587 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 0.323755 | 0.490 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 0.493533 | 0.307 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 0.515297 | 0.288 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 0.564811 | 0.248 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 0.437465 | 0.359 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 0.332329 | 0.478 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 0.443207 | 0.353 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 0.536617 | 0.270 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 0.097734 | 1.010 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 0.455525 | 0.341 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 0.455525 | 0.341 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 0.129878 | 0.886 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 0.157553 | 0.803 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 0.317135 | 0.499 | 0 | 0 |
| PKA activation | R-HSA-163615 | 0.219602 | 0.658 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 0.354758 | 0.450 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 0.354758 | 0.450 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 0.464323 | 0.333 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 0.517263 | 0.286 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 0.341591 | 0.466 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 0.495686 | 0.305 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 0.268221 | 0.572 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 0.419298 | 0.377 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 0.527789 | 0.278 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 0.527789 | 0.278 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 0.405397 | 0.392 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 0.427731 | 0.369 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 0.423315 | 0.373 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 0.493533 | 0.307 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 0.473444 | 0.325 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 0.473444 | 0.325 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 0.442909 | 0.354 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 0.145410 | 0.837 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 0.555970 | 0.255 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 0.210218 | 0.677 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 0.242510 | 0.615 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 0.546377 | 0.263 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 0.546377 | 0.263 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 0.108581 | 0.964 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 0.133401 | 0.875 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 0.143369 | 0.844 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 0.286840 | 0.542 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 0.261783 | 0.582 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 0.265464 | 0.576 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 0.561475 | 0.251 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 0.561475 | 0.251 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 0.561475 | 0.251 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 0.561475 | 0.251 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 0.419298 | 0.377 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 0.443207 | 0.353 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 0.498264 | 0.303 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 0.104882 | 0.979 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 0.178640 | 0.748 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 0.415740 | 0.381 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 0.206835 | 0.684 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 0.345076 | 0.462 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 0.165617 | 0.781 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 0.131070 | 0.882 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 0.202790 | 0.693 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 0.177480 | 0.751 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 0.317135 | 0.499 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 0.219602 | 0.658 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 0.176135 | 0.754 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 0.191812 | 0.717 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 0.345076 | 0.462 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 0.345076 | 0.462 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 0.091818 | 1.037 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 0.427494 | 0.369 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 0.152069 | 0.818 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 0.462225 | 0.335 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 0.141332 | 0.850 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 0.422803 | 0.374 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 0.527789 | 0.278 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 0.507608 | 0.294 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 0.558474 | 0.253 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 0.514367 | 0.289 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 0.543121 | 0.265 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 0.359986 | 0.444 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 0.205503 | 0.687 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 0.267151 | 0.573 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 0.227097 | 0.644 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 0.104704 | 0.980 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 0.382277 | 0.418 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 0.382277 | 0.418 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 0.491191 | 0.309 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 0.289621 | 0.538 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 0.180653 | 0.743 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 0.391251 | 0.408 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 0.154763 | 0.810 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 0.091818 | 1.037 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 0.425537 | 0.371 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 0.376088 | 0.425 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 0.274352 | 0.562 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 0.100869 | 0.996 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 0.202790 | 0.693 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 0.202790 | 0.693 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 0.279023 | 0.554 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 0.233336 | 0.632 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 0.233336 | 0.632 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 0.233336 | 0.632 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 0.288794 | 0.539 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 0.354758 | 0.450 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 0.464323 | 0.333 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 0.223611 | 0.651 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 0.517263 | 0.286 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 0.220505 | 0.657 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 0.257433 | 0.589 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 0.260554 | 0.584 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 0.396687 | 0.402 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 0.558474 | 0.253 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 0.442909 | 0.354 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 0.267210 | 0.573 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 0.251910 | 0.599 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 0.154864 | 0.810 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 0.519250 | 0.285 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 0.165617 | 0.781 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 0.108581 | 0.964 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 0.116412 | 0.934 | 0 | 0 |
| Vasopressin-like receptors | R-HSA-388479 | 0.464323 | 0.333 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 0.223611 | 0.651 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 0.240296 | 0.619 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 0.400933 | 0.397 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 0.382784 | 0.417 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 0.491191 | 0.309 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 0.580705 | 0.236 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 0.561475 | 0.251 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 0.096364 | 1.016 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 0.096364 | 1.016 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 0.316916 | 0.499 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 0.223611 | 0.651 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 0.114603 | 0.941 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 0.568222 | 0.245 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 0.357292 | 0.447 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 0.301272 | 0.521 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 0.241581 | 0.617 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 0.403754 | 0.394 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 0.421418 | 0.375 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 0.400613 | 0.397 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 0.527722 | 0.278 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 0.458621 | 0.339 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 0.470535 | 0.327 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 0.551231 | 0.259 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 0.280858 | 0.552 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 0.105556 | 0.977 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 0.437845 | 0.359 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 0.509554 | 0.293 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 0.127627 | 0.894 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 0.474630 | 0.324 | 0 | 0 |
| SDK interactions | R-HSA-373756 | 0.187833 | 0.726 | 0 | 0 |
| ARL13B-mediated ciliary trafficking of INPP5E | R-HSA-5624958 | 0.268079 | 0.572 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 0.268079 | 0.572 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 0.165617 | 0.781 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 0.103568 | 0.985 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 0.405581 | 0.392 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 0.405581 | 0.392 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 0.405581 | 0.392 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 0.133401 | 0.875 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 0.260874 | 0.584 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 0.219602 | 0.658 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 0.464323 | 0.333 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 0.178656 | 0.748 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 0.391616 | 0.407 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 0.391616 | 0.407 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 0.165968 | 0.780 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 0.165968 | 0.780 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 0.090043 | 1.046 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 0.517263 | 0.286 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 0.462225 | 0.335 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 0.462225 | 0.335 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 0.462225 | 0.335 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 0.294055 | 0.532 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 0.428381 | 0.368 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 0.428381 | 0.368 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 0.291134 | 0.536 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 0.495686 | 0.305 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 0.564974 | 0.248 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 0.564974 | 0.248 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 0.564974 | 0.248 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 0.381165 | 0.419 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 0.399013 | 0.399 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 0.471367 | 0.327 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 0.257049 | 0.590 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 0.536617 | 0.270 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 0.394062 | 0.404 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 0.438353 | 0.358 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 0.438353 | 0.358 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 0.553654 | 0.257 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 0.308033 | 0.511 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 0.132544 | 0.878 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 0.481129 | 0.318 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 0.198721 | 0.702 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 0.294055 | 0.532 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 0.462840 | 0.335 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 0.115475 | 0.938 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 0.389087 | 0.410 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 0.350700 | 0.455 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 0.427731 | 0.369 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 0.558474 | 0.253 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 0.392807 | 0.406 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 0.481995 | 0.317 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 0.464794 | 0.333 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 0.444760 | 0.352 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 0.267554 | 0.573 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 0.183277 | 0.737 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 0.576420 | 0.239 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 0.106395 | 0.973 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 0.562399 | 0.250 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 0.131070 | 0.882 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 0.155018 | 0.810 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 0.286840 | 0.542 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 0.198721 | 0.702 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 0.211855 | 0.674 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 0.426037 | 0.371 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 0.235352 | 0.628 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 0.253210 | 0.597 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 0.455525 | 0.341 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 0.442909 | 0.354 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 0.438059 | 0.358 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 0.281392 | 0.551 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 0.382252 | 0.418 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 0.307893 | 0.512 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 0.322157 | 0.492 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 0.322157 | 0.492 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 0.467238 | 0.330 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 0.202790 | 0.693 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 0.354758 | 0.450 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 0.517263 | 0.286 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 0.564974 | 0.248 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 0.557107 | 0.254 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 0.195059 | 0.710 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 0.560493 | 0.251 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 0.136080 | 0.866 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 0.292305 | 0.534 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 0.174159 | 0.759 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 0.122486 | 0.912 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 0.558513 | 0.253 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 0.292330 | 0.534 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 0.412217 | 0.385 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 0.165217 | 0.782 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 0.333156 | 0.477 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 0.292305 | 0.534 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 0.558474 | 0.253 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 0.500888 | 0.300 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 0.162791 | 0.788 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 0.095247 | 1.021 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 0.261783 | 0.582 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 0.365564 | 0.437 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 0.283451 | 0.548 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 0.143425 | 0.843 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 0.400933 | 0.397 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 0.523589 | 0.281 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 0.456942 | 0.340 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 0.294055 | 0.532 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 0.268079 | 0.572 | 0 | 0 |
| DSCAM interactions | R-HSA-376172 | 0.340401 | 0.468 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 0.180195 | 0.744 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 0.138525 | 0.858 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 0.405581 | 0.392 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 0.111582 | 0.952 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 0.288794 | 0.539 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 0.354758 | 0.450 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 0.354758 | 0.450 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 0.464323 | 0.333 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 0.427494 | 0.369 | 0 | 0 |
| Biosynthesis of DPAn-3-derived 13-series resolvins | R-HSA-9026403 | 0.517263 | 0.286 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 0.382252 | 0.418 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 0.564974 | 0.248 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 0.448850 | 0.348 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 0.507608 | 0.294 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 0.443207 | 0.353 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 0.491191 | 0.309 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 0.481995 | 0.317 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 0.540023 | 0.268 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 0.473444 | 0.325 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 0.321359 | 0.493 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 0.532727 | 0.273 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 0.423315 | 0.373 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 0.301272 | 0.521 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 0.271069 | 0.567 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 0.131070 | 0.882 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 0.379681 | 0.421 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 0.481800 | 0.317 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 0.558474 | 0.253 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 0.361908 | 0.441 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 0.518270 | 0.285 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 0.558474 | 0.253 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 0.313507 | 0.504 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 0.240766 | 0.618 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 0.240766 | 0.618 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 0.170100 | 0.769 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 0.316916 | 0.499 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 0.427494 | 0.369 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 0.247462 | 0.606 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 0.281635 | 0.550 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 0.557107 | 0.254 | 0 | 0 |
| Kinesins | R-HSA-983189 | 0.561475 | 0.251 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 0.141442 | 0.849 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 0.455525 | 0.341 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 0.314087 | 0.503 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 0.233336 | 0.632 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 0.115475 | 0.938 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 0.563124 | 0.249 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 0.382252 | 0.418 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 0.131070 | 0.882 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 0.279023 | 0.554 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 0.279023 | 0.554 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 0.405581 | 0.392 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 0.317135 | 0.499 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 0.132315 | 0.878 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 0.354758 | 0.450 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 0.464323 | 0.333 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 0.564974 | 0.248 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 0.314073 | 0.503 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 0.364299 | 0.439 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 0.462840 | 0.335 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 0.137601 | 0.861 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 0.389864 | 0.409 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 0.288794 | 0.539 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 0.527789 | 0.278 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 0.587710 | 0.231 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 0.370010 | 0.432 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 0.428381 | 0.368 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 0.569890 | 0.244 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 0.317135 | 0.499 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 0.427494 | 0.369 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 0.564974 | 0.248 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 0.564974 | 0.248 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 0.557107 | 0.254 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 0.219602 | 0.658 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 0.467355 | 0.330 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 0.190585 | 0.720 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 0.111582 | 0.952 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 0.505502 | 0.296 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 0.126415 | 0.898 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 0.179286 | 0.746 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 0.174479 | 0.758 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 0.402990 | 0.395 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 0.507608 | 0.294 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 0.391616 | 0.407 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 0.515297 | 0.288 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 0.580705 | 0.236 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 0.133842 | 0.873 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 0.085954 | 1.066 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 0.588360 | 0.230 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 0.591376 | 0.228 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 0.591747 | 0.228 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 0.594336 | 0.226 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 0.603491 | 0.219 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 0.603491 | 0.219 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 0.604446 | 0.219 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 0.605163 | 0.218 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 0.606410 | 0.217 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 0.607972 | 0.216 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 0.607972 | 0.216 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 0.607972 | 0.216 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 0.607972 | 0.216 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 0.607972 | 0.216 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 0.607972 | 0.216 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 0.607972 | 0.216 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 0.607972 | 0.216 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 0.607972 | 0.216 | 0 | 0 |
| Lipid particle organization | R-HSA-8964572 | 0.607972 | 0.216 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 0.607972 | 0.216 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 0.608428 | 0.216 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 0.608428 | 0.216 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 0.611627 | 0.214 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 0.615229 | 0.211 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 0.615482 | 0.211 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 0.615482 | 0.211 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 0.615482 | 0.211 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 0.615482 | 0.211 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 0.615482 | 0.211 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 0.615482 | 0.211 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 0.615482 | 0.211 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 0.615482 | 0.211 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 0.615482 | 0.211 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 0.615482 | 0.211 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 0.616173 | 0.210 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 0.616764 | 0.210 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 0.616764 | 0.210 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 0.616764 | 0.210 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 0.616764 | 0.210 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 0.625441 | 0.204 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 0.634660 | 0.197 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 0.634818 | 0.197 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 0.635393 | 0.197 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 0.635393 | 0.197 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 0.641795 | 0.193 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 0.641795 | 0.193 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 0.641795 | 0.193 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 0.641795 | 0.193 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 0.641795 | 0.193 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 0.641795 | 0.193 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 0.641795 | 0.193 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 0.644883 | 0.191 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 0.644883 | 0.191 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 0.645455 | 0.190 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 0.646542 | 0.189 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 0.646542 | 0.189 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 0.646542 | 0.189 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 0.646542 | 0.189 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 0.646542 | 0.189 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 0.646542 | 0.189 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 0.646542 | 0.189 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 0.646723 | 0.189 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 0.646723 | 0.189 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 0.646723 | 0.189 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 0.646723 | 0.189 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 0.646723 | 0.189 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 0.646723 | 0.189 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 0.646723 | 0.189 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 0.646723 | 0.189 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 0.646723 | 0.189 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 0.646723 | 0.189 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 0.646723 | 0.189 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 0.646723 | 0.189 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 0.646723 | 0.189 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 0.646723 | 0.189 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 0.646723 | 0.189 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 0.664980 | 0.177 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 0.666665 | 0.176 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 0.666665 | 0.176 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 0.666665 | 0.176 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 0.666665 | 0.176 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 0.666784 | 0.176 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 0.666784 | 0.176 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 0.670848 | 0.173 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 0.674483 | 0.171 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 0.676294 | 0.170 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 0.678829 | 0.168 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 0.681645 | 0.166 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 0.681645 | 0.166 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 0.681645 | 0.166 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 0.681645 | 0.166 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 0.681645 | 0.166 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 0.681645 | 0.166 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 0.681645 | 0.166 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 0.681645 | 0.166 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 0.681645 | 0.166 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 0.681645 | 0.166 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 0.685976 | 0.164 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 0.686166 | 0.164 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 0.686166 | 0.164 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 0.688970 | 0.162 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 0.690121 | 0.161 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 0.690121 | 0.161 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 0.690121 | 0.161 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 0.690121 | 0.161 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 0.690844 | 0.161 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 0.694128 | 0.159 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 0.694447 | 0.158 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 0.695820 | 0.158 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 0.695820 | 0.158 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 0.695820 | 0.158 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 0.695820 | 0.158 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 0.697010 | 0.157 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 0.698573 | 0.156 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 0.700887 | 0.154 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 0.702106 | 0.154 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 0.702106 | 0.154 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 0.703851 | 0.153 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 0.704692 | 0.152 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 0.704692 | 0.152 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 0.704692 | 0.152 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 0.704692 | 0.152 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 0.705799 | 0.151 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 0.712012 | 0.148 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 0.712198 | 0.147 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 0.712198 | 0.147 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 0.712198 | 0.147 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 0.712198 | 0.147 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 0.712198 | 0.147 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 0.712198 | 0.147 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 0.712198 | 0.147 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 0.713082 | 0.147 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 0.713117 | 0.147 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 0.713117 | 0.147 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 0.713117 | 0.147 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 0.713117 | 0.147 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 0.713117 | 0.147 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 0.713117 | 0.147 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 0.713117 | 0.147 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 0.713117 | 0.147 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 0.713117 | 0.147 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 0.713117 | 0.147 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 0.713117 | 0.147 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 0.713117 | 0.147 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 0.713117 | 0.147 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 0.719427 | 0.143 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 0.719427 | 0.143 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 0.719427 | 0.143 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 0.719427 | 0.143 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 0.719427 | 0.143 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 0.719427 | 0.143 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 0.719427 | 0.143 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 0.719827 | 0.143 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 0.720001 | 0.143 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 0.721708 | 0.142 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 0.721708 | 0.142 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 0.724939 | 0.140 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 0.726768 | 0.139 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 0.726768 | 0.139 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 0.732941 | 0.135 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 0.732941 | 0.135 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 0.732941 | 0.135 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 0.732941 | 0.135 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 0.734389 | 0.134 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 0.734389 | 0.134 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 0.736455 | 0.133 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 0.736726 | 0.133 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 0.739208 | 0.131 | 0 | 0 |
| S Phase | R-HSA-69242 | 0.741297 | 0.130 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 0.741479 | 0.130 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 0.741479 | 0.130 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 0.741479 | 0.130 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 0.741479 | 0.130 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 0.741479 | 0.130 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 0.741479 | 0.130 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 0.741479 | 0.130 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 0.741479 | 0.130 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 0.741479 | 0.130 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 0.744777 | 0.128 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 0.746432 | 0.127 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 0.746432 | 0.127 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 0.748742 | 0.126 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 0.748742 | 0.126 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 0.748742 | 0.126 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 0.748742 | 0.126 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 0.748742 | 0.126 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 0.749514 | 0.125 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 0.752210 | 0.124 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 0.752398 | 0.124 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 0.752398 | 0.124 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 0.752398 | 0.124 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 0.752398 | 0.124 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 0.752398 | 0.124 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 0.752398 | 0.124 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 0.752398 | 0.124 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 0.753209 | 0.123 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 0.753209 | 0.123 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 0.755213 | 0.122 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 0.755227 | 0.122 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 0.756944 | 0.121 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 0.759014 | 0.120 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 0.759014 | 0.120 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 0.764285 | 0.117 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 0.767039 | 0.115 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 0.767039 | 0.115 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 0.767039 | 0.115 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 0.767039 | 0.115 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 0.767039 | 0.115 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 0.767039 | 0.115 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 0.767039 | 0.115 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 0.767039 | 0.115 | 0 | 0 |
| Biosynthesis of DPAn-3-derived maresins | R-HSA-9026290 | 0.767039 | 0.115 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 0.767039 | 0.115 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 0.768963 | 0.114 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 0.769235 | 0.114 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 0.770442 | 0.113 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 0.770442 | 0.113 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 0.770619 | 0.113 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 0.770619 | 0.113 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 0.770619 | 0.113 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 0.770619 | 0.113 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 0.770619 | 0.113 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 0.770619 | 0.113 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 0.770619 | 0.113 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 0.770619 | 0.113 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 0.770619 | 0.113 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 0.773119 | 0.112 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 0.775379 | 0.110 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 0.775650 | 0.110 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 0.775650 | 0.110 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 0.779297 | 0.108 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 0.782708 | 0.106 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 0.784875 | 0.105 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 0.784875 | 0.105 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 0.784875 | 0.105 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 0.784875 | 0.105 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 0.787659 | 0.104 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 0.787659 | 0.104 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 0.787659 | 0.104 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 0.787659 | 0.104 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 0.787659 | 0.104 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 0.787659 | 0.104 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 0.788225 | 0.103 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 0.788225 | 0.103 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 0.788225 | 0.103 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 0.788572 | 0.103 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 0.788944 | 0.103 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 0.788944 | 0.103 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 0.790073 | 0.102 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 0.790073 | 0.102 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 0.790073 | 0.102 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 0.790073 | 0.102 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 0.790073 | 0.102 | 0 | 0 |
| Anchoring fibril formation | R-HSA-2214320 | 0.790073 | 0.102 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 0.790073 | 0.102 | 0 | 0 |
| Uptake of dietary cobalamins into enterocytes | R-HSA-9758881 | 0.790073 | 0.102 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 0.791881 | 0.101 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 0.793930 | 0.100 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 0.793930 | 0.100 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 0.797561 | 0.098 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 0.798548 | 0.098 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 0.798548 | 0.098 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 0.798548 | 0.098 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 0.799302 | 0.097 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 0.800230 | 0.097 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 0.800230 | 0.097 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 0.800230 | 0.097 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 0.800592 | 0.097 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 0.803574 | 0.095 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 0.803574 | 0.095 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 0.803574 | 0.095 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 0.803574 | 0.095 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 0.806359 | 0.093 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 0.807599 | 0.093 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 0.809386 | 0.092 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 0.810831 | 0.091 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 0.810831 | 0.091 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 0.810831 | 0.091 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 0.810831 | 0.091 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 0.810831 | 0.091 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 0.810831 | 0.091 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 0.810831 | 0.091 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 0.810831 | 0.091 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 0.810831 | 0.091 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 0.810831 | 0.091 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 0.810831 | 0.091 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 0.810831 | 0.091 | 0 | 0 |
| Biosynthesis of DPAn-3-derived protectins and resolvins | R-HSA-9026286 | 0.810831 | 0.091 | 0 | 0 |
| Diseases associated with surfactant metabolism | R-HSA-5687613 | 0.810831 | 0.091 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 0.810831 | 0.091 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 0.810831 | 0.091 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 0.810831 | 0.091 | 0 | 0 |
| Estrogen biosynthesis | R-HSA-193144 | 0.810831 | 0.091 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 0.810831 | 0.091 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 0.811678 | 0.091 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 0.814918 | 0.089 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 0.816439 | 0.088 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 0.817521 | 0.088 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 0.818419 | 0.087 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 0.818419 | 0.087 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 0.818419 | 0.087 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 0.818419 | 0.087 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 0.818419 | 0.087 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 0.819595 | 0.086 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 0.819595 | 0.086 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 0.822584 | 0.085 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 0.823713 | 0.084 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 0.823713 | 0.084 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 0.824752 | 0.084 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 0.824960 | 0.084 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 0.828544 | 0.082 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 0.828544 | 0.082 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 0.829537 | 0.081 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 0.829537 | 0.081 | 0 | 0 |
| Mtb iron assimilation by chelation | R-HSA-1222449 | 0.829537 | 0.081 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 0.829537 | 0.081 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 0.829537 | 0.081 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 0.829537 | 0.081 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 0.829537 | 0.081 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 0.829537 | 0.081 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 0.829537 | 0.081 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 0.829988 | 0.081 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 0.830628 | 0.081 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 0.832249 | 0.080 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 0.832249 | 0.080 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 0.832249 | 0.080 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 0.832249 | 0.080 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 0.832249 | 0.080 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 0.832448 | 0.080 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 0.832962 | 0.079 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 0.835256 | 0.078 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 0.835256 | 0.078 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 0.835256 | 0.078 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 0.835364 | 0.078 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 0.835377 | 0.078 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 0.837136 | 0.077 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 0.840842 | 0.075 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 0.843147 | 0.074 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 0.845122 | 0.073 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 0.845122 | 0.073 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 0.845122 | 0.073 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 0.846395 | 0.072 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 0.846395 | 0.072 | 0 | 0 |
| Biosynthesis of E-series 18(R)-resolvins | R-HSA-9023661 | 0.846395 | 0.072 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 0.846395 | 0.072 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 0.846395 | 0.072 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 0.846395 | 0.072 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 0.846395 | 0.072 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 0.846395 | 0.072 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 0.846395 | 0.072 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 0.852200 | 0.069 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 0.852543 | 0.069 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 0.854578 | 0.068 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 0.856396 | 0.067 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 0.856396 | 0.067 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 0.857090 | 0.067 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 0.857090 | 0.067 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 0.857090 | 0.067 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 0.857090 | 0.067 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 0.857090 | 0.067 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 0.857090 | 0.067 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 0.857090 | 0.067 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 0.860343 | 0.065 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 0.860840 | 0.065 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 0.860840 | 0.065 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 0.861093 | 0.065 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 0.861093 | 0.065 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 0.861093 | 0.065 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 0.861586 | 0.065 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 0.861586 | 0.065 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 0.861586 | 0.065 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 0.861586 | 0.065 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 0.861586 | 0.065 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 0.861586 | 0.065 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 0.861586 | 0.065 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 0.861586 | 0.065 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 0.861586 | 0.065 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 0.861586 | 0.065 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 0.861586 | 0.065 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 0.861586 | 0.065 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 0.861586 | 0.065 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 0.861586 | 0.065 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 0.866048 | 0.062 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 0.867086 | 0.062 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 0.868207 | 0.061 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 0.868207 | 0.061 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 0.869524 | 0.061 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 0.869524 | 0.061 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 0.869714 | 0.061 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 0.869714 | 0.061 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 0.869915 | 0.061 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 0.875123 | 0.058 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 0.875276 | 0.058 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 0.875276 | 0.058 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 0.875276 | 0.058 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 0.875276 | 0.058 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 0.875276 | 0.058 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 0.875276 | 0.058 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 0.877511 | 0.057 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 0.877511 | 0.057 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 0.878160 | 0.056 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 0.878523 | 0.056 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 0.878523 | 0.056 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 0.878523 | 0.056 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 0.878523 | 0.056 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 0.883648 | 0.054 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 0.885070 | 0.053 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 0.887612 | 0.052 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 0.887612 | 0.052 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 0.887612 | 0.052 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 0.887612 | 0.052 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 0.887612 | 0.052 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 0.887612 | 0.052 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 0.887612 | 0.052 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 0.887612 | 0.052 | 0 | 0 |
| Vitamin B6 activation to pyridoxal phosphate | R-HSA-964975 | 0.887612 | 0.052 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 0.887612 | 0.052 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 0.887612 | 0.052 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 0.887612 | 0.052 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 0.887612 | 0.052 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 0.887612 | 0.052 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 0.887937 | 0.052 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 0.888089 | 0.052 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 0.888514 | 0.051 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 0.889746 | 0.051 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 0.889746 | 0.051 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 0.889746 | 0.051 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 0.891651 | 0.050 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 0.891651 | 0.050 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 0.891651 | 0.050 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 0.892219 | 0.050 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 0.893581 | 0.049 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 0.896952 | 0.047 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 0.896952 | 0.047 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 0.896952 | 0.047 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 0.898729 | 0.046 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 0.898729 | 0.046 | 0 | 0 |
| Biosynthesis of aspirin-triggered D-series resolvins | R-HSA-9020265 | 0.898729 | 0.046 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 0.898729 | 0.046 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 0.898729 | 0.046 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 0.898729 | 0.046 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 0.898976 | 0.046 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 0.898976 | 0.046 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 0.899156 | 0.046 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 0.899156 | 0.046 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 0.899717 | 0.046 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 0.899994 | 0.046 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 0.900271 | 0.046 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 0.900547 | 0.045 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 0.905157 | 0.043 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 0.905157 | 0.043 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 0.908747 | 0.042 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 0.908747 | 0.042 | 0 | 0 |
| Biosynthesis of Lipoxins (LX) | R-HSA-2142700 | 0.908747 | 0.042 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 0.908747 | 0.042 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 0.908747 | 0.042 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 0.908747 | 0.042 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 0.908747 | 0.042 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 0.908747 | 0.042 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 0.909339 | 0.041 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 0.911231 | 0.040 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 0.911376 | 0.040 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 0.911738 | 0.040 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 0.912688 | 0.040 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 0.912688 | 0.040 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 0.912748 | 0.040 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 0.912748 | 0.040 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 0.912748 | 0.040 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 0.912775 | 0.040 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 0.912775 | 0.040 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 0.913245 | 0.039 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 0.915604 | 0.038 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 0.917053 | 0.038 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 0.917775 | 0.037 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 0.917775 | 0.037 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 0.917775 | 0.037 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 0.917775 | 0.037 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 0.917775 | 0.037 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 0.917775 | 0.037 | 0 | 0 |
| Crosslinking of collagen fibrils | R-HSA-2243919 | 0.917775 | 0.037 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 0.917775 | 0.037 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 0.917775 | 0.037 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 0.918431 | 0.037 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 0.919766 | 0.036 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 0.919766 | 0.036 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 0.919804 | 0.036 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 0.922084 | 0.035 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 0.922402 | 0.035 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 0.922402 | 0.035 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 0.922557 | 0.035 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 0.923010 | 0.035 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 0.924700 | 0.034 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 0.925909 | 0.033 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 0.925909 | 0.033 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 0.925909 | 0.033 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 0.925909 | 0.033 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 0.925909 | 0.033 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 0.925909 | 0.033 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 0.925909 | 0.033 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 0.926250 | 0.033 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 0.926250 | 0.033 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 0.926250 | 0.033 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 0.926250 | 0.033 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 0.926250 | 0.033 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 0.927229 | 0.033 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 0.927229 | 0.033 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 0.927433 | 0.033 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 0.927440 | 0.033 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 0.930085 | 0.031 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 0.931150 | 0.031 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 0.931831 | 0.031 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 0.932180 | 0.031 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 0.932180 | 0.031 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 0.933240 | 0.030 | 0 | 0 |
| Biosynthesis of E-series 18(S)-resolvins | R-HSA-9018896 | 0.933240 | 0.030 | 0 | 0 |
| Phenylalanine metabolism | R-HSA-8964208 | 0.933240 | 0.030 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 0.933240 | 0.030 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 0.933240 | 0.030 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 0.933240 | 0.030 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 0.935114 | 0.029 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 0.935229 | 0.029 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 0.937012 | 0.028 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 0.937761 | 0.028 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 0.937761 | 0.028 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 0.937761 | 0.028 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 0.937823 | 0.028 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 0.938424 | 0.028 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 0.939846 | 0.027 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 0.939846 | 0.027 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 0.939846 | 0.027 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 0.939846 | 0.027 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 0.939846 | 0.027 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 0.940829 | 0.026 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 0.942857 | 0.026 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 0.942857 | 0.026 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 0.942857 | 0.026 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 0.943630 | 0.025 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 0.943904 | 0.025 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 0.945569 | 0.024 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 0.945798 | 0.024 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 0.945798 | 0.024 | 0 | 0 |
| Biosynthesis of D-series resolvins | R-HSA-9018676 | 0.945798 | 0.024 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 0.945798 | 0.024 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 0.945798 | 0.024 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 0.945798 | 0.024 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 0.947553 | 0.023 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 0.947553 | 0.023 | 0 | 0 |
| Depurination | R-HSA-73927 | 0.947553 | 0.023 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 0.947789 | 0.023 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 0.948262 | 0.023 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 0.948262 | 0.023 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 0.948262 | 0.023 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 0.949698 | 0.022 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 0.949698 | 0.022 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 0.950438 | 0.022 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 0.950787 | 0.022 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 0.951162 | 0.022 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 0.951162 | 0.022 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 0.951162 | 0.022 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 0.951162 | 0.022 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 0.951162 | 0.022 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 0.951162 | 0.022 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 0.951162 | 0.022 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 0.951248 | 0.022 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 0.951795 | 0.021 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 0.951880 | 0.021 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 0.951880 | 0.021 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 0.952062 | 0.021 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 0.952234 | 0.021 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 0.953075 | 0.021 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 0.953236 | 0.021 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 0.953236 | 0.021 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 0.955181 | 0.020 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 0.955181 | 0.020 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 0.955601 | 0.020 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 0.955865 | 0.020 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 0.955865 | 0.020 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 0.955995 | 0.020 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 0.955995 | 0.020 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 0.955995 | 0.020 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 0.955995 | 0.020 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 0.955995 | 0.020 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 0.955995 | 0.020 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 0.956020 | 0.020 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 0.957259 | 0.019 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 0.958653 | 0.018 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 0.958893 | 0.018 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 0.959533 | 0.018 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 0.959533 | 0.018 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 0.959533 | 0.018 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 0.959533 | 0.018 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 0.960059 | 0.018 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 0.960350 | 0.018 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 0.960350 | 0.018 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 0.960350 | 0.018 | 0 | 0 |
| Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives | R-HSA-9027604 | 0.960350 | 0.018 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 0.960350 | 0.018 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 0.961859 | 0.017 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 0.962907 | 0.016 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 0.963419 | 0.016 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 0.964274 | 0.016 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 0.964274 | 0.016 | 0 | 0 |
| Attachment of bacteria to epithelial cells | R-HSA-9638630 | 0.964274 | 0.016 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 0.964802 | 0.016 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 0.965145 | 0.015 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 0.965345 | 0.015 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 0.965716 | 0.015 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 0.966010 | 0.015 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 0.966010 | 0.015 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 0.966010 | 0.015 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 0.966614 | 0.015 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 0.967810 | 0.014 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 0.967810 | 0.014 | 0 | 0 |
| Biosynthesis of DPAn-3 SPMs | R-HSA-9025094 | 0.967810 | 0.014 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 0.967810 | 0.014 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 0.967810 | 0.014 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 0.967810 | 0.014 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 0.967810 | 0.014 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 0.967810 | 0.014 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 0.968598 | 0.014 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 0.968862 | 0.014 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 0.969804 | 0.013 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 0.969904 | 0.013 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 0.969904 | 0.013 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 0.970997 | 0.013 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 0.970997 | 0.013 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 0.970997 | 0.013 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 0.971483 | 0.013 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 0.972184 | 0.012 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 0.972952 | 0.012 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 0.973868 | 0.011 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 0.973868 | 0.011 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 0.973868 | 0.011 | 0 | 0 |
| Biosynthesis of EPA-derived SPMs | R-HSA-9018679 | 0.973868 | 0.011 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 0.973868 | 0.011 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 0.973868 | 0.011 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 0.973891 | 0.011 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 0.973891 | 0.011 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 0.973891 | 0.011 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 0.974300 | 0.011 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 0.976101 | 0.011 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 0.976263 | 0.010 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 0.976455 | 0.010 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 0.976455 | 0.010 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 0.976455 | 0.010 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 0.976455 | 0.010 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 0.976455 | 0.010 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 0.976455 | 0.010 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 0.976520 | 0.010 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 0.976524 | 0.010 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 0.978130 | 0.010 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 0.978130 | 0.010 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 0.978786 | 0.009 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 0.978786 | 0.009 | 0 | 0 |
| Biosynthesis of DPA-derived SPMs | R-HSA-9018683 | 0.978786 | 0.009 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 0.979281 | 0.009 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 0.979867 | 0.009 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 0.979991 | 0.009 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 0.980140 | 0.009 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 0.980886 | 0.008 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 0.980886 | 0.008 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 0.980886 | 0.008 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 0.981639 | 0.008 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 0.981960 | 0.008 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 0.982779 | 0.008 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 0.982779 | 0.008 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 0.982779 | 0.008 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 0.983179 | 0.007 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 0.984484 | 0.007 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 0.984484 | 0.007 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 0.984484 | 0.007 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 0.984699 | 0.007 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 0.984699 | 0.007 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 0.985353 | 0.006 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 0.985353 | 0.006 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 0.986021 | 0.006 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 0.986021 | 0.006 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 0.986021 | 0.006 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 0.986021 | 0.006 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 0.986021 | 0.006 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 0.986229 | 0.006 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 0.987184 | 0.006 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 0.987405 | 0.006 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 0.987405 | 0.006 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 0.987405 | 0.006 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 0.987405 | 0.006 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 0.987405 | 0.006 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 0.987405 | 0.006 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 0.987418 | 0.005 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 0.987559 | 0.005 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 0.988323 | 0.005 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 0.988538 | 0.005 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 0.988652 | 0.005 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 0.988652 | 0.005 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 0.988652 | 0.005 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 0.989776 | 0.004 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 0.989776 | 0.004 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 0.989776 | 0.004 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 0.989776 | 0.004 | 0 | 0 |
| Phenylalanine and tyrosine metabolism | R-HSA-8963691 | 0.989776 | 0.004 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 0.990258 | 0.004 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 0.990258 | 0.004 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 0.990486 | 0.004 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 0.990789 | 0.004 | 0 | 0 |
| Biofilm formation | R-HSA-9931953 | 0.990789 | 0.004 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 0.990789 | 0.004 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 0.991104 | 0.004 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 0.991104 | 0.004 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 0.991179 | 0.004 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 0.991701 | 0.004 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 0.991701 | 0.004 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 0.991763 | 0.004 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 0.991834 | 0.004 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 0.992420 | 0.003 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 0.992523 | 0.003 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 0.992523 | 0.003 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 0.992523 | 0.003 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 0.992587 | 0.003 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 0.993235 | 0.003 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 0.993235 | 0.003 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 0.993264 | 0.003 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 0.993264 | 0.003 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 0.993586 | 0.003 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 0.993932 | 0.003 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 0.993932 | 0.003 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 0.993932 | 0.003 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 0.993932 | 0.003 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 0.994102 | 0.003 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 0.994231 | 0.003 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 0.994368 | 0.002 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 0.994661 | 0.002 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 0.994750 | 0.002 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 0.994760 | 0.002 | 0 | 0 |
| Defensins | R-HSA-1461973 | 0.995075 | 0.002 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 0.995079 | 0.002 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 0.995315 | 0.002 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 0.995563 | 0.002 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 0.995563 | 0.002 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 0.995767 | 0.002 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 0.995792 | 0.002 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 0.996002 | 0.002 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 0.996399 | 0.002 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 0.996399 | 0.002 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 0.996449 | 0.002 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 0.996449 | 0.002 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 0.996755 | 0.001 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 0.996805 | 0.001 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 0.997007 | 0.001 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 0.997077 | 0.001 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 0.997104 | 0.001 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 0.997219 | 0.001 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 0.997252 | 0.001 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 0.997367 | 0.001 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 0.997367 | 0.001 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 0.997367 | 0.001 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 0.997367 | 0.001 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 0.997551 | 0.001 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 0.997551 | 0.001 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 0.997863 | 0.001 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 0.997877 | 0.001 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 0.997877 | 0.001 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 0.998336 | 0.001 | 0 | 0 |
| Protein folding | R-HSA-391251 | 0.998363 | 0.001 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 0.998467 | 0.001 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 0.998548 | 0.001 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 0.998732 | 0.001 | 0 | 0 |
| Digestion | R-HSA-8935690 | 0.998732 | 0.001 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 0.998843 | 0.001 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 0.998868 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 0.998935 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 0.999042 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 0.999073 | 0.000 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 0.999073 | 0.000 | 0 | 0 |
| Sialic acid metabolism | R-HSA-4085001 | 0.999073 | 0.000 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 0.999165 | 0.000 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 0.999165 | 0.000 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 0.999236 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 0.999248 | 0.000 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 0.999248 | 0.000 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 0.999255 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 0.999382 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 0.999390 | 0.000 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 0.999390 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 0.999428 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 0.999450 | 0.000 | 0 | 0 |
| Latent infection - Other responses of Mtb to phagocytosis | R-HSA-1222499 | 0.999505 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 0.999510 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 0.999511 | 0.000 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 0.999554 | 0.000 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 0.999590 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 0.999598 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 0.999598 | 0.000 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 0.999706 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 0.999706 | 0.000 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 0.999734 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 0.999735 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 0.999755 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 0.999755 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 0.999761 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 0.999762 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 0.999803 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 0.999807 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 0.999826 | 0.000 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 0.999826 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 0.999828 | 0.000 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 0.999828 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 0.999871 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 0.999873 | 0.000 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 0.999873 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 0.999907 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 0.999913 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 0.999913 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 0.999916 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 0.999960 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 0.999960 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 0.999963 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 0.999972 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 0.999987 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 0.999994 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 0.999994 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 0.999995 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 0.999996 | 0.000 | 0 | 0 |
| Immune System | R-HSA-168256 | 0.999996 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 0.999996 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 0.999996 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 0.999998 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 0.999998 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 0.999999 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 0.999999 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 0.999999 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 0.999999 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 0.999999 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 1.000000 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.000000 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.000000 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 1.000000 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 1.000000 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cellular responses to stress | R-HSA-2262752 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 2.220446e-16 | 15.654 | 0 | 0 |
| M Phase | R-HSA-68886 | 7.771561e-16 | 15.109 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 7.771561e-16 | 15.109 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.998401e-15 | 14.699 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 6.550316e-15 | 14.184 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 9.425793e-14 | 13.026 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 7.793766e-13 | 12.108 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 7.556067e-12 | 11.122 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 1.243894e-11 | 10.905 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 3.978395e-11 | 10.400 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 6.655987e-11 | 10.177 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.179992e-10 | 9.928 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.179992e-10 | 9.928 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.094946e-10 | 9.961 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.331931e-10 | 9.876 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 3.906822e-10 | 9.408 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 4.548215e-10 | 9.342 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 9.269161e-10 | 9.033 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 1.033921e-09 | 8.986 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 1.197714e-09 | 8.922 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.292151e-09 | 8.889 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.500966e-09 | 8.824 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 2.339336e-09 | 8.631 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 2.339336e-09 | 8.631 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 2.344833e-09 | 8.630 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 2.464081e-09 | 8.608 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 2.901510e-09 | 8.537 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 3.269431e-09 | 8.486 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 3.387842e-09 | 8.470 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 3.798160e-09 | 8.420 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 3.926295e-09 | 8.406 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 5.669118e-09 | 8.246 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 7.689646e-09 | 8.114 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 8.979725e-09 | 8.047 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 1.130007e-08 | 7.947 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 1.130007e-08 | 7.947 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 1.087115e-08 | 7.964 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.165315e-08 | 7.934 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 1.195684e-08 | 7.922 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.259729e-08 | 7.900 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 1.636074e-08 | 7.786 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 1.763125e-08 | 7.754 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.728554e-08 | 7.762 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.902486e-08 | 7.721 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 2.092708e-08 | 7.679 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 2.112815e-08 | 7.675 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.015579e-08 | 7.696 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.015579e-08 | 7.696 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 2.708850e-08 | 7.567 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 3.182968e-08 | 7.497 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 3.180962e-08 | 7.497 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 3.215719e-08 | 7.493 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 3.482424e-08 | 7.458 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 3.587986e-08 | 7.445 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 3.913234e-08 | 7.407 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 4.983915e-08 | 7.302 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 6.047000e-08 | 7.218 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 6.562599e-08 | 7.183 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 7.434235e-08 | 7.129 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 8.149281e-08 | 7.089 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 8.149281e-08 | 7.089 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 8.955593e-08 | 7.048 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 9.364884e-08 | 7.028 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 9.846379e-08 | 7.007 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 1.296461e-07 | 6.887 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.331110e-07 | 6.876 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 1.431175e-07 | 6.844 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 1.507519e-07 | 6.822 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.709181e-07 | 6.767 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 1.719857e-07 | 6.765 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 1.840418e-07 | 6.735 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 2.194667e-07 | 6.659 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 2.258121e-07 | 6.646 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 2.565670e-07 | 6.591 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 2.594327e-07 | 6.586 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 2.830280e-07 | 6.548 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 2.940459e-07 | 6.532 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 3.211488e-07 | 6.493 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 3.470892e-07 | 6.460 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 4.314294e-07 | 6.365 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 4.567701e-07 | 6.340 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 4.946725e-07 | 6.306 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 5.541781e-07 | 6.256 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 5.639661e-07 | 6.249 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 6.365124e-07 | 6.196 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 6.180301e-07 | 6.209 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 7.649569e-07 | 6.116 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 7.994353e-07 | 6.097 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 8.019464e-07 | 6.096 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 8.303314e-07 | 6.081 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 9.363109e-07 | 6.029 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 9.676745e-07 | 6.014 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.130693e-06 | 5.947 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 1.149131e-06 | 5.940 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.229055e-06 | 5.910 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 1.554395e-06 | 5.808 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 1.554395e-06 | 5.808 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 1.686309e-06 | 5.773 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.651812e-06 | 5.782 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 2.146396e-06 | 5.668 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 2.354871e-06 | 5.628 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 2.579974e-06 | 5.588 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 2.608444e-06 | 5.584 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 2.836894e-06 | 5.547 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 3.091805e-06 | 5.510 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 3.093091e-06 | 5.510 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 3.158176e-06 | 5.501 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 3.394657e-06 | 5.469 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 3.641299e-06 | 5.439 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 4.103710e-06 | 5.387 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 4.028687e-06 | 5.395 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 4.103710e-06 | 5.387 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 3.911756e-06 | 5.408 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 4.202440e-06 | 5.376 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 4.426814e-06 | 5.354 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 4.910333e-06 | 5.309 | 0 | 0 |
| Depurination | R-HSA-73927 | 5.225570e-06 | 5.282 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 5.299551e-06 | 5.276 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 6.035106e-06 | 5.219 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 6.035106e-06 | 5.219 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 6.162277e-06 | 5.210 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 6.260869e-06 | 5.203 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 6.265607e-06 | 5.203 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 6.975042e-06 | 5.156 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 7.498168e-06 | 5.125 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 8.025138e-06 | 5.096 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 8.364037e-06 | 5.078 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 9.097491e-06 | 5.041 | 0 | 0 |
| Kinesins | R-HSA-983189 | 9.347317e-06 | 5.029 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.012639e-05 | 4.995 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 1.030695e-05 | 4.987 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 1.170589e-05 | 4.932 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 1.228229e-05 | 4.911 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.259243e-05 | 4.900 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 1.263526e-05 | 4.898 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 1.426091e-05 | 4.846 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 1.387661e-05 | 4.858 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 1.478215e-05 | 4.830 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 1.478215e-05 | 4.830 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 1.478215e-05 | 4.830 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 1.478215e-05 | 4.830 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.488917e-05 | 4.827 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 1.545740e-05 | 4.811 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.578174e-05 | 4.802 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.586990e-05 | 4.799 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 1.740566e-05 | 4.759 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 1.740566e-05 | 4.759 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 1.913120e-05 | 4.718 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.879276e-05 | 4.726 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 1.974587e-05 | 4.705 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 1.974587e-05 | 4.705 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 1.994231e-05 | 4.700 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 2.013322e-05 | 4.696 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 2.013322e-05 | 4.696 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 2.364222e-05 | 4.626 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 2.433353e-05 | 4.614 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 2.735322e-05 | 4.563 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 3.119528e-05 | 4.506 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 3.512208e-05 | 4.454 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 3.691025e-05 | 4.433 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 3.978954e-05 | 4.400 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 4.472208e-05 | 4.349 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 4.470712e-05 | 4.350 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 4.589197e-05 | 4.338 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 4.724006e-05 | 4.326 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 4.955685e-05 | 4.305 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 5.463044e-05 | 4.263 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 5.463044e-05 | 4.263 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 6.293507e-05 | 4.201 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 6.478184e-05 | 4.189 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 6.573640e-05 | 4.182 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 7.504925e-05 | 4.125 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 7.685627e-05 | 4.114 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 7.960796e-05 | 4.099 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 8.354085e-05 | 4.078 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 9.293402e-05 | 4.032 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 1.056702e-04 | 3.976 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.019543e-04 | 3.992 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 9.985212e-05 | 4.001 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 1.032776e-04 | 3.986 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 1.076728e-04 | 3.968 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.131437e-04 | 3.946 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.257848e-04 | 3.900 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 1.488766e-04 | 3.827 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.646751e-04 | 3.783 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.658856e-04 | 3.780 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 1.731920e-04 | 3.761 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 1.786495e-04 | 3.748 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 2.060845e-04 | 3.686 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 2.169163e-04 | 3.664 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 2.232308e-04 | 3.651 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 2.265380e-04 | 3.645 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 2.317113e-04 | 3.635 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 2.410790e-04 | 3.618 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 2.516568e-04 | 3.599 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 2.775224e-04 | 3.557 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 2.535898e-04 | 3.596 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 2.628731e-04 | 3.580 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 2.546932e-04 | 3.594 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 2.535898e-04 | 3.596 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 2.794083e-04 | 3.554 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 2.904989e-04 | 3.537 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 2.937798e-04 | 3.532 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 2.941494e-04 | 3.531 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 3.026546e-04 | 3.519 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 3.125241e-04 | 3.505 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 3.257071e-04 | 3.487 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 3.355584e-04 | 3.474 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 3.423549e-04 | 3.466 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 3.621393e-04 | 3.441 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 3.829707e-04 | 3.417 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 3.909623e-04 | 3.408 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 4.070561e-04 | 3.390 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 4.130724e-04 | 3.384 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 4.300753e-04 | 3.366 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 4.586660e-04 | 3.339 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 4.695857e-04 | 3.328 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 5.024129e-04 | 3.299 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 5.050418e-04 | 3.297 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 5.782402e-04 | 3.238 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 5.782402e-04 | 3.238 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 5.367214e-04 | 3.270 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 5.367214e-04 | 3.270 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 5.616472e-04 | 3.251 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 7.008479e-04 | 3.154 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 7.037118e-04 | 3.153 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 7.239578e-04 | 3.140 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 7.494645e-04 | 3.125 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 7.494645e-04 | 3.125 | 0 | 0 |
| Translation | R-HSA-72766 | 7.548259e-04 | 3.122 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 7.823067e-04 | 3.107 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 7.921427e-04 | 3.101 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 8.080946e-04 | 3.093 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 8.690116e-04 | 3.061 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 9.032657e-04 | 3.044 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 9.340749e-04 | 3.030 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 9.762785e-04 | 3.010 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 9.843496e-04 | 3.007 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 1.012821e-03 | 2.994 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 1.111062e-03 | 2.954 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 1.114421e-03 | 2.953 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 1.119392e-03 | 2.951 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.189896e-03 | 2.924 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 1.293774e-03 | 2.888 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 1.293774e-03 | 2.888 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 1.280544e-03 | 2.893 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 1.293774e-03 | 2.888 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 1.347487e-03 | 2.870 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 1.155344e-03 | 2.937 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 1.406135e-03 | 2.852 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 1.456756e-03 | 2.837 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 1.498912e-03 | 2.824 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.524023e-03 | 2.817 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 1.583872e-03 | 2.800 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 1.583872e-03 | 2.800 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 1.583872e-03 | 2.800 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 1.645734e-03 | 2.784 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 1.709056e-03 | 2.767 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.709056e-03 | 2.767 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 1.812663e-03 | 2.742 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 1.929859e-03 | 2.714 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 1.959537e-03 | 2.708 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 2.016813e-03 | 2.695 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 2.016813e-03 | 2.695 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 2.102048e-03 | 2.677 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 2.250071e-03 | 2.648 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 2.292925e-03 | 2.640 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 2.332524e-03 | 2.632 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 2.354087e-03 | 2.628 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 2.357031e-03 | 2.628 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 2.361326e-03 | 2.627 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 2.476433e-03 | 2.606 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 2.611653e-03 | 2.583 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 2.827758e-03 | 2.549 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 2.862170e-03 | 2.543 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 2.862170e-03 | 2.543 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 3.229108e-03 | 2.491 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 3.368248e-03 | 2.473 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 3.084349e-03 | 2.511 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 3.342826e-03 | 2.476 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 3.342826e-03 | 2.476 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 3.437545e-03 | 2.464 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 3.437545e-03 | 2.464 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 3.071839e-03 | 2.513 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 3.437545e-03 | 2.464 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 3.414915e-03 | 2.467 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 3.392410e-03 | 2.469 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 3.437545e-03 | 2.464 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 3.071839e-03 | 2.513 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 2.942305e-03 | 2.531 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 3.023367e-03 | 2.520 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 3.476803e-03 | 2.459 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 3.476803e-03 | 2.459 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 3.476803e-03 | 2.459 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 3.476803e-03 | 2.459 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 3.476803e-03 | 2.459 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 3.610585e-03 | 2.442 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 3.731201e-03 | 2.428 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 3.836308e-03 | 2.416 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 3.844990e-03 | 2.415 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 4.102030e-03 | 2.387 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 4.104661e-03 | 2.387 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 4.276434e-03 | 2.369 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 4.284638e-03 | 2.368 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 4.296512e-03 | 2.367 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 4.494911e-03 | 2.347 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 4.633264e-03 | 2.334 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 4.864983e-03 | 2.313 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 5.381708e-03 | 2.269 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 5.381708e-03 | 2.269 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 5.381708e-03 | 2.269 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 5.480514e-03 | 2.261 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 5.480514e-03 | 2.261 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 5.480514e-03 | 2.261 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 5.523684e-03 | 2.258 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 5.736155e-03 | 2.241 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 5.736155e-03 | 2.241 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 5.771594e-03 | 2.239 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 5.914614e-03 | 2.228 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 5.966899e-03 | 2.224 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 6.093054e-03 | 2.215 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 6.181486e-03 | 2.209 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 7.809978e-03 | 2.107 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 6.973988e-03 | 2.157 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 6.950453e-03 | 2.158 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 6.296073e-03 | 2.201 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 6.617585e-03 | 2.179 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 7.809978e-03 | 2.107 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 6.725651e-03 | 2.172 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 7.524606e-03 | 2.124 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 7.441057e-03 | 2.128 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 6.375135e-03 | 2.196 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 7.528327e-03 | 2.123 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 7.371046e-03 | 2.132 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 7.217089e-03 | 2.142 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 7.843876e-03 | 2.105 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 7.843876e-03 | 2.105 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 7.843876e-03 | 2.105 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 7.978387e-03 | 2.098 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 7.978387e-03 | 2.098 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 7.978387e-03 | 2.098 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 7.978387e-03 | 2.098 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 7.978387e-03 | 2.098 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 7.978387e-03 | 2.098 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 7.978387e-03 | 2.098 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 7.978387e-03 | 2.098 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 7.978387e-03 | 2.098 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 7.978387e-03 | 2.098 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 7.978387e-03 | 2.098 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 8.129508e-03 | 2.090 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 8.204798e-03 | 2.086 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 8.204798e-03 | 2.086 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 8.245938e-03 | 2.084 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 8.367910e-03 | 2.077 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 8.479511e-03 | 2.072 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 8.479511e-03 | 2.072 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 8.943311e-03 | 2.049 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 9.001461e-03 | 2.046 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 9.101482e-03 | 2.041 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 9.121212e-03 | 2.040 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 9.122153e-03 | 2.040 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 9.148611e-03 | 2.039 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 9.148611e-03 | 2.039 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 9.339639e-03 | 2.030 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 9.446142e-03 | 2.025 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 9.446142e-03 | 2.025 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 9.626224e-03 | 2.017 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.001504e-02 | 1.999 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 1.020653e-02 | 1.991 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.046853e-02 | 1.980 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 1.046853e-02 | 1.980 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 1.046853e-02 | 1.980 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 1.046853e-02 | 1.980 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 1.050931e-02 | 1.978 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 1.050931e-02 | 1.978 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 1.050931e-02 | 1.978 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.050931e-02 | 1.978 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.075101e-02 | 1.969 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 1.075101e-02 | 1.969 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 1.075101e-02 | 1.969 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 1.075101e-02 | 1.969 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 1.437032e-02 | 1.843 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 1.437032e-02 | 1.843 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 1.437032e-02 | 1.843 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 1.437032e-02 | 1.843 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 1.333426e-02 | 1.875 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.333426e-02 | 1.875 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 1.431524e-02 | 1.844 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 1.201357e-02 | 1.920 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 1.122816e-02 | 1.950 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 1.139698e-02 | 1.943 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.431524e-02 | 1.844 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 1.434318e-02 | 1.843 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 1.434318e-02 | 1.843 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 1.420699e-02 | 1.847 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 1.431524e-02 | 1.844 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 1.122816e-02 | 1.950 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 1.122816e-02 | 1.950 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 1.426410e-02 | 1.846 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 1.426410e-02 | 1.846 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 1.114874e-02 | 1.953 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 1.207833e-02 | 1.918 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 1.291650e-02 | 1.889 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 1.302413e-02 | 1.885 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 1.154441e-02 | 1.938 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 1.249806e-02 | 1.903 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 1.426410e-02 | 1.846 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 1.302413e-02 | 1.885 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 1.437032e-02 | 1.843 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 1.381958e-02 | 1.860 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 1.441158e-02 | 1.841 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 1.448085e-02 | 1.839 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 1.502759e-02 | 1.823 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 1.502759e-02 | 1.823 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 1.502759e-02 | 1.823 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.536304e-02 | 1.814 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 1.536304e-02 | 1.814 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 1.609371e-02 | 1.793 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.670752e-02 | 1.777 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.687540e-02 | 1.773 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 1.698504e-02 | 1.770 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 1.725193e-02 | 1.763 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 1.761064e-02 | 1.754 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 1.761064e-02 | 1.754 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 1.761064e-02 | 1.754 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 1.761064e-02 | 1.754 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 1.761064e-02 | 1.754 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 1.786275e-02 | 1.748 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 1.804832e-02 | 1.744 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 1.809508e-02 | 1.742 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 1.855028e-02 | 1.732 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 1.872764e-02 | 1.728 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.872764e-02 | 1.728 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 1.872764e-02 | 1.728 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 1.872764e-02 | 1.728 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 1.872764e-02 | 1.728 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 1.912939e-02 | 1.718 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 1.912939e-02 | 1.718 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 1.917463e-02 | 1.717 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 1.950742e-02 | 1.710 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.970237e-02 | 1.705 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 1.971027e-02 | 1.705 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 1.971027e-02 | 1.705 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.984169e-02 | 1.702 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.984169e-02 | 1.702 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 1.995993e-02 | 1.700 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 2.006500e-02 | 1.698 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 2.018643e-02 | 1.695 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 2.018643e-02 | 1.695 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 2.027732e-02 | 1.693 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 2.075504e-02 | 1.683 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.078286e-02 | 1.682 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 2.241544e-02 | 1.649 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 2.241544e-02 | 1.649 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 2.241544e-02 | 1.649 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 2.264936e-02 | 1.645 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 2.272571e-02 | 1.643 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 2.272571e-02 | 1.643 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 2.313209e-02 | 1.636 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 2.313209e-02 | 1.636 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 2.326279e-02 | 1.633 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 2.387456e-02 | 1.622 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 2.387456e-02 | 1.622 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 2.387456e-02 | 1.622 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 2.387456e-02 | 1.622 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 2.387456e-02 | 1.622 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 2.387456e-02 | 1.622 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 2.387456e-02 | 1.622 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 2.387456e-02 | 1.622 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 2.463078e-02 | 1.609 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 2.472244e-02 | 1.607 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 2.472244e-02 | 1.607 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.512500e-02 | 1.600 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 2.512500e-02 | 1.600 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 2.537985e-02 | 1.596 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 2.537985e-02 | 1.596 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 2.549090e-02 | 1.594 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 2.593144e-02 | 1.586 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 2.593144e-02 | 1.586 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 2.593144e-02 | 1.586 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 2.688182e-02 | 1.571 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 2.849195e-02 | 1.545 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 2.861537e-02 | 1.543 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 2.888578e-02 | 1.539 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 2.985376e-02 | 1.525 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 3.001153e-02 | 1.523 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 3.001153e-02 | 1.523 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 3.001153e-02 | 1.523 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 3.001153e-02 | 1.523 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 3.023383e-02 | 1.520 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 3.023383e-02 | 1.520 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 3.083364e-02 | 1.511 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 3.099065e-02 | 1.509 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 3.107528e-02 | 1.508 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 3.117536e-02 | 1.506 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 3.160494e-02 | 1.500 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 3.160494e-02 | 1.500 | 0 | 0 |
| Inhibition of Host mRNA Processing and RNA Silencing | R-HSA-168315 | 3.711661e-02 | 1.430 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 3.435616e-02 | 1.464 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 4.771598e-02 | 1.321 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 4.340634e-02 | 1.362 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 3.669844e-02 | 1.435 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 4.443215e-02 | 1.352 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 4.443215e-02 | 1.352 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 4.237998e-02 | 1.373 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 3.556831e-02 | 1.449 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 3.556831e-02 | 1.449 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 4.582359e-02 | 1.339 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 4.582359e-02 | 1.339 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 4.582359e-02 | 1.339 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 4.448381e-02 | 1.352 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 4.303818e-02 | 1.366 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 4.303818e-02 | 1.366 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 4.303818e-02 | 1.366 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 4.735127e-02 | 1.325 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 4.735127e-02 | 1.325 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 4.133835e-02 | 1.384 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 4.133835e-02 | 1.384 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 3.915285e-02 | 1.407 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 4.237998e-02 | 1.373 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 4.501914e-02 | 1.347 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 3.597853e-02 | 1.444 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 3.381012e-02 | 1.471 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 3.381012e-02 | 1.471 | 0 | 0 |
| Protein folding | R-HSA-391251 | 3.192635e-02 | 1.496 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 4.443215e-02 | 1.352 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 3.669844e-02 | 1.435 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 4.443215e-02 | 1.352 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 4.582359e-02 | 1.339 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 4.087453e-02 | 1.389 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 4.237998e-02 | 1.373 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 3.711661e-02 | 1.430 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 3.199888e-02 | 1.495 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 4.308499e-02 | 1.366 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 4.617868e-02 | 1.336 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 4.771598e-02 | 1.321 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 4.771598e-02 | 1.321 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 3.401519e-02 | 1.468 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 4.735127e-02 | 1.325 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 4.582359e-02 | 1.339 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 3.779776e-02 | 1.423 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 4.093269e-02 | 1.388 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 4.443215e-02 | 1.352 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 3.556831e-02 | 1.449 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 3.250689e-02 | 1.488 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 4.005811e-02 | 1.397 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 4.585417e-02 | 1.339 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 3.594428e-02 | 1.444 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 4.448381e-02 | 1.352 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 4.087453e-02 | 1.389 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 3.377912e-02 | 1.471 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 3.211721e-02 | 1.493 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 4.833212e-02 | 1.316 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 4.908076e-02 | 1.309 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 4.922947e-02 | 1.308 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 4.939042e-02 | 1.306 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 4.945405e-02 | 1.306 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 4.945405e-02 | 1.306 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 5.160867e-02 | 1.287 | 0 | 0 |
| S Phase | R-HSA-69242 | 5.181914e-02 | 1.286 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 5.187000e-02 | 1.285 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 5.187000e-02 | 1.285 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 5.194914e-02 | 1.284 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 5.268018e-02 | 1.278 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 5.281644e-02 | 1.277 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 5.285113e-02 | 1.277 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 5.285113e-02 | 1.277 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 5.285113e-02 | 1.277 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 5.306877e-02 | 1.275 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 5.306877e-02 | 1.275 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 5.306877e-02 | 1.275 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 5.306877e-02 | 1.275 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 5.410851e-02 | 1.267 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 5.410851e-02 | 1.267 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 5.568450e-02 | 1.254 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 5.683763e-02 | 1.245 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 5.721149e-02 | 1.243 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 5.721149e-02 | 1.243 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 5.721149e-02 | 1.243 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 5.721149e-02 | 1.243 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 5.721149e-02 | 1.243 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 5.836903e-02 | 1.234 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 5.840614e-02 | 1.234 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 5.857837e-02 | 1.232 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 5.979947e-02 | 1.223 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 6.184526e-02 | 1.209 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 6.184526e-02 | 1.209 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 6.191181e-02 | 1.208 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 6.191181e-02 | 1.208 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 6.202180e-02 | 1.207 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 6.232015e-02 | 1.205 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 6.261271e-02 | 1.203 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 6.261271e-02 | 1.203 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 6.261271e-02 | 1.203 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 6.261271e-02 | 1.203 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 6.323948e-02 | 1.199 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 6.323948e-02 | 1.199 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 6.359734e-02 | 1.197 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 6.444569e-02 | 1.191 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 6.453593e-02 | 1.190 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 6.453593e-02 | 1.190 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 6.453593e-02 | 1.190 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 6.487637e-02 | 1.188 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 6.565793e-02 | 1.183 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 6.565793e-02 | 1.183 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 6.565793e-02 | 1.183 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 6.586821e-02 | 1.181 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 6.586821e-02 | 1.181 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 6.610528e-02 | 1.180 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 6.610528e-02 | 1.180 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 6.610528e-02 | 1.180 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 6.655751e-02 | 1.177 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 6.755710e-02 | 1.170 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 6.874482e-02 | 1.163 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 6.874482e-02 | 1.163 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 6.943310e-02 | 1.158 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 7.168081e-02 | 1.145 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 7.168081e-02 | 1.145 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 7.396746e-02 | 1.131 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 7.396746e-02 | 1.131 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 7.422015e-02 | 1.129 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 7.479390e-02 | 1.126 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 7.479390e-02 | 1.126 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 7.553281e-02 | 1.122 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 7.564307e-02 | 1.121 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 7.797017e-02 | 1.108 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 7.797017e-02 | 1.108 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 7.806056e-02 | 1.108 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 7.930461e-02 | 1.101 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 7.936245e-02 | 1.100 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 7.936245e-02 | 1.100 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 7.936245e-02 | 1.100 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 7.936245e-02 | 1.100 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 7.936245e-02 | 1.100 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 8.014829e-02 | 1.096 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 8.027688e-02 | 1.095 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 8.078190e-02 | 1.093 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 8.078190e-02 | 1.093 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 8.078190e-02 | 1.093 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 8.271758e-02 | 1.082 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 8.271758e-02 | 1.082 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 8.318786e-02 | 1.080 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 8.439523e-02 | 1.074 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 8.439523e-02 | 1.074 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 8.439523e-02 | 1.074 | 0 | 0 |
| PKA activation | R-HSA-163615 | 8.439523e-02 | 1.074 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 8.439523e-02 | 1.074 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 8.439523e-02 | 1.074 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 8.439523e-02 | 1.074 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 8.505261e-02 | 1.070 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 9.016241e-02 | 1.045 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 9.062339e-02 | 1.043 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 9.062339e-02 | 1.043 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 9.249579e-02 | 1.034 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 9.383033e-02 | 1.028 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 9.383033e-02 | 1.028 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 9.542946e-02 | 1.020 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 9.542946e-02 | 1.020 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 9.542946e-02 | 1.020 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 9.542946e-02 | 1.020 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 9.542946e-02 | 1.020 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 9.542946e-02 | 1.020 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 9.542946e-02 | 1.020 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 9.542946e-02 | 1.020 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 9.542946e-02 | 1.020 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 9.542946e-02 | 1.020 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 9.542946e-02 | 1.020 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 9.542946e-02 | 1.020 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 9.542946e-02 | 1.020 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 9.542946e-02 | 1.020 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 9.542946e-02 | 1.020 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 9.542946e-02 | 1.020 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 9.542946e-02 | 1.020 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 9.542946e-02 | 1.020 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 9.592317e-02 | 1.018 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 9.659939e-02 | 1.015 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 9.659939e-02 | 1.015 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.717771e-02 | 1.012 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 9.717771e-02 | 1.012 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 9.827690e-02 | 1.008 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 9.903672e-02 | 1.004 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 9.951257e-02 | 1.002 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.001692e-01 | 0.999 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.001692e-01 | 0.999 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 1.001692e-01 | 0.999 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 1.001692e-01 | 0.999 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 1.013944e-01 | 0.994 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 1.013944e-01 | 0.994 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 1.013944e-01 | 0.994 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 1.059193e-01 | 0.975 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 1.059193e-01 | 0.975 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 1.062713e-01 | 0.974 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 1.062713e-01 | 0.974 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 1.066473e-01 | 0.972 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 1.066473e-01 | 0.972 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 1.071618e-01 | 0.970 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 1.078999e-01 | 0.967 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 1.096433e-01 | 0.960 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.096433e-01 | 0.960 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 1.116347e-01 | 0.952 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 1.116347e-01 | 0.952 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 1.130770e-01 | 0.947 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 1.137465e-01 | 0.944 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.143662e-01 | 0.942 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.143662e-01 | 0.942 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 1.154063e-01 | 0.938 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 1.163913e-01 | 0.934 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.169000e-01 | 0.932 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 1.180749e-01 | 0.928 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 1.180749e-01 | 0.928 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 1.180749e-01 | 0.928 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 1.180749e-01 | 0.928 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 1.206189e-01 | 0.919 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 1.212088e-01 | 0.916 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 1.212088e-01 | 0.916 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.212088e-01 | 0.916 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 1.212088e-01 | 0.916 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 1.212088e-01 | 0.916 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.212088e-01 | 0.916 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 1.817572e-01 | 0.741 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 1.817572e-01 | 0.741 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 1.817572e-01 | 0.741 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 1.817572e-01 | 0.741 | 0 | 0 |
| RPIA deficiency: failed conversion of R5P to RU5P | R-HSA-5659996 | 1.817572e-01 | 0.741 | 0 | 0 |
| RPIA deficiency: failed conversion of RU5P to R5P | R-HSA-6791461 | 1.817572e-01 | 0.741 | 0 | 0 |
| Defective ACTH causes obesity and POMCD | R-HSA-5579031 | 1.817572e-01 | 0.741 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 1.224539e-01 | 0.912 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.224539e-01 | 0.912 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 1.224539e-01 | 0.912 | 0 | 0 |
| IRS activation | R-HSA-74713 | 1.564929e-01 | 0.806 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 1.564929e-01 | 0.806 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 1.920298e-01 | 0.717 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 1.920298e-01 | 0.717 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 1.920298e-01 | 0.717 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 1.920298e-01 | 0.717 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 1.920298e-01 | 0.717 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.436973e-01 | 0.843 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.436973e-01 | 0.843 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 1.436973e-01 | 0.843 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 2.284690e-01 | 0.641 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 2.284690e-01 | 0.641 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 2.284690e-01 | 0.641 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 1.438196e-01 | 0.842 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 1.921949e-01 | 0.716 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 1.234921e-01 | 0.908 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 1.624066e-01 | 0.789 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 2.177982e-01 | 0.662 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 1.818047e-01 | 0.740 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 1.818047e-01 | 0.740 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 2.440460e-01 | 0.613 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 2.440460e-01 | 0.613 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 2.019181e-01 | 0.695 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 1.435243e-01 | 0.843 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 1.571160e-01 | 0.804 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 1.571160e-01 | 0.804 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.860543e-01 | 0.730 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 2.226498e-01 | 0.652 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 1.297309e-01 | 0.887 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 2.398295e-01 | 0.620 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 1.571160e-01 | 0.804 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.680026e-01 | 0.775 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 1.234921e-01 | 0.908 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 2.212045e-01 | 0.655 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 1.245481e-01 | 0.905 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 1.438196e-01 | 0.842 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 1.564929e-01 | 0.806 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 1.436973e-01 | 0.843 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 2.127373e-01 | 0.672 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 1.564929e-01 | 0.806 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.534367e-01 | 0.814 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 1.834868e-01 | 0.736 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 2.032317e-01 | 0.692 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 1.680026e-01 | 0.775 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 1.698533e-01 | 0.770 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 1.329911e-01 | 0.876 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 2.226498e-01 | 0.652 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 1.382130e-01 | 0.859 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 2.279126e-01 | 0.642 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 2.209123e-01 | 0.656 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 1.920298e-01 | 0.717 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 1.680026e-01 | 0.775 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 1.435243e-01 | 0.843 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 1.798587e-01 | 0.745 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 1.223990e-01 | 0.912 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 1.711416e-01 | 0.767 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.586840e-01 | 0.799 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.384699e-01 | 0.859 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.512723e-01 | 0.820 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 1.920298e-01 | 0.717 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 1.438196e-01 | 0.842 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 1.818047e-01 | 0.740 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 2.019181e-01 | 0.695 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 1.223990e-01 | 0.912 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 1.610563e-01 | 0.793 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 2.209123e-01 | 0.656 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 1.576774e-01 | 0.802 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 1.799158e-01 | 0.745 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 2.439028e-01 | 0.613 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 1.984896e-01 | 0.702 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 1.738341e-01 | 0.760 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 2.047931e-01 | 0.689 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 2.284690e-01 | 0.641 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 2.177982e-01 | 0.662 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 2.177982e-01 | 0.662 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 2.177982e-01 | 0.662 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 2.439028e-01 | 0.613 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.009756e-01 | 0.697 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 1.263937e-01 | 0.898 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 1.865838e-01 | 0.729 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 1.984896e-01 | 0.702 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.858765e-01 | 0.731 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 1.453167e-01 | 0.838 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 1.302166e-01 | 0.885 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 1.984896e-01 | 0.702 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 1.680026e-01 | 0.775 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 1.921750e-01 | 0.716 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 1.920298e-01 | 0.717 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 2.284690e-01 | 0.641 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 1.858765e-01 | 0.731 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 2.009756e-01 | 0.697 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 2.390374e-01 | 0.622 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 1.402970e-01 | 0.853 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 1.234921e-01 | 0.908 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 2.209123e-01 | 0.656 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 1.223990e-01 | 0.912 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 1.541914e-01 | 0.812 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.479581e-01 | 0.830 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 2.304837e-01 | 0.637 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 1.920298e-01 | 0.717 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 1.921949e-01 | 0.716 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 1.834868e-01 | 0.736 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 1.369918e-01 | 0.863 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 1.834868e-01 | 0.736 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 1.920298e-01 | 0.717 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 2.324232e-01 | 0.634 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 1.664186e-01 | 0.779 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 1.223990e-01 | 0.912 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 2.440460e-01 | 0.613 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 1.438196e-01 | 0.842 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 1.984896e-01 | 0.702 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 1.818047e-01 | 0.740 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 2.439028e-01 | 0.613 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 2.474242e-01 | 0.607 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 2.486929e-01 | 0.604 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 2.492276e-01 | 0.603 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 2.501805e-01 | 0.602 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 2.545910e-01 | 0.594 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 2.575478e-01 | 0.589 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 2.598509e-01 | 0.585 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 2.598509e-01 | 0.585 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 2.598509e-01 | 0.585 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 2.598509e-01 | 0.585 | 0 | 0 |
| Defective MMADHC causes MMAHCD | R-HSA-3359473 | 2.598509e-01 | 0.585 | 0 | 0 |
| Defective SLC26A2 causes chondrodysplasias | R-HSA-3560792 | 2.598509e-01 | 0.585 | 0 | 0 |
| TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | R-HSA-6791055 | 2.598509e-01 | 0.585 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 2.598509e-01 | 0.585 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 2.598509e-01 | 0.585 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 2.598509e-01 | 0.585 | 0 | 0 |
| TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | R-HSA-6791462 | 2.598509e-01 | 0.585 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 2.598509e-01 | 0.585 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 2.598509e-01 | 0.585 | 0 | 0 |
| Nef mediated downregulation of CD28 cell surface expression | R-HSA-164939 | 2.598509e-01 | 0.585 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 2.598509e-01 | 0.585 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 2.612963e-01 | 0.583 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.615946e-01 | 0.582 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 2.653152e-01 | 0.576 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 2.653152e-01 | 0.576 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 2.653152e-01 | 0.576 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 2.653152e-01 | 0.576 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 2.653152e-01 | 0.576 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 2.655812e-01 | 0.576 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 2.655812e-01 | 0.576 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 2.664725e-01 | 0.574 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 2.707570e-01 | 0.567 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 2.707570e-01 | 0.567 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 2.707570e-01 | 0.567 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 2.763844e-01 | 0.558 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 2.763844e-01 | 0.558 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 2.763844e-01 | 0.558 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 2.763844e-01 | 0.558 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 2.850716e-01 | 0.545 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 2.859738e-01 | 0.544 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 2.875918e-01 | 0.541 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 2.876455e-01 | 0.541 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 2.947923e-01 | 0.530 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 2.954884e-01 | 0.529 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 2.954884e-01 | 0.529 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 2.977619e-01 | 0.526 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 2.977619e-01 | 0.526 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 2.977619e-01 | 0.526 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 2.977619e-01 | 0.526 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 2.977619e-01 | 0.526 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 2.991981e-01 | 0.524 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 3.021590e-01 | 0.520 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 3.021590e-01 | 0.520 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 3.021590e-01 | 0.520 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 3.021590e-01 | 0.520 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 3.098441e-01 | 0.509 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 3.106836e-01 | 0.508 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 3.112679e-01 | 0.507 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 3.148021e-01 | 0.502 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 3.148021e-01 | 0.502 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 3.148021e-01 | 0.502 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 3.152212e-01 | 0.501 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 3.163575e-01 | 0.500 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 3.163575e-01 | 0.500 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 3.164625e-01 | 0.500 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 3.164625e-01 | 0.500 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 3.225663e-01 | 0.491 | 0 | 0 |
| Defective ALG9 causes CDG-1l | R-HSA-4720454 | 3.304955e-01 | 0.481 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 3.304955e-01 | 0.481 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 3.304955e-01 | 0.481 | 0 | 0 |
| TWIK related potassium channel (TREK) | R-HSA-1299503 | 3.304955e-01 | 0.481 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 3.304955e-01 | 0.481 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 3.304955e-01 | 0.481 | 0 | 0 |
| Interleukin-33 signaling | R-HSA-9014843 | 3.304955e-01 | 0.481 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 3.304955e-01 | 0.481 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 3.322264e-01 | 0.479 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 3.322514e-01 | 0.479 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 3.322514e-01 | 0.479 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 3.322514e-01 | 0.479 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 3.338742e-01 | 0.476 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 3.338742e-01 | 0.476 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 3.338742e-01 | 0.476 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 3.342692e-01 | 0.476 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 3.342692e-01 | 0.476 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 3.354498e-01 | 0.474 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 3.386657e-01 | 0.470 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 3.386657e-01 | 0.470 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 3.386657e-01 | 0.470 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 3.386657e-01 | 0.470 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 3.386657e-01 | 0.470 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 3.386657e-01 | 0.470 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 3.386657e-01 | 0.470 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 3.386657e-01 | 0.470 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 3.386657e-01 | 0.470 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 3.490982e-01 | 0.457 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 3.513937e-01 | 0.454 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 3.513937e-01 | 0.454 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 3.520421e-01 | 0.453 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 3.520421e-01 | 0.453 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 3.520421e-01 | 0.453 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 3.538349e-01 | 0.451 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.538349e-01 | 0.451 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 3.538349e-01 | 0.451 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 3.538349e-01 | 0.451 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 3.547316e-01 | 0.450 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 3.547316e-01 | 0.450 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 3.547506e-01 | 0.450 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 3.594919e-01 | 0.444 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 3.689827e-01 | 0.433 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 3.725033e-01 | 0.429 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 3.744069e-01 | 0.427 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 3.744069e-01 | 0.427 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 3.744069e-01 | 0.427 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 3.744069e-01 | 0.427 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 3.744069e-01 | 0.427 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 3.744069e-01 | 0.427 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 3.745640e-01 | 0.426 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 3.745640e-01 | 0.426 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 3.745640e-01 | 0.426 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 3.745640e-01 | 0.426 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 3.745640e-01 | 0.426 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 3.745640e-01 | 0.426 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 3.745640e-01 | 0.426 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 3.745640e-01 | 0.426 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 3.745640e-01 | 0.426 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 3.745640e-01 | 0.426 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 3.754815e-01 | 0.425 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 3.772070e-01 | 0.423 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 3.772070e-01 | 0.423 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 3.790453e-01 | 0.421 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 3.790453e-01 | 0.421 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 3.790453e-01 | 0.421 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 3.790453e-01 | 0.421 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 3.835837e-01 | 0.416 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 3.866039e-01 | 0.413 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 3.893627e-01 | 0.410 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 3.930541e-01 | 0.406 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 3.930541e-01 | 0.406 | 0 | 0 |
| Defective MMACHC causes MAHCC | R-HSA-3359474 | 3.944010e-01 | 0.404 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 3.944010e-01 | 0.404 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 3.944010e-01 | 0.404 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 3.944010e-01 | 0.404 | 0 | 0 |
| CASP5-mediated substrate cleavage | R-HSA-9960525 | 3.944010e-01 | 0.404 | 0 | 0 |
| CASP4-mediated substrate cleavage | R-HSA-9960519 | 3.944010e-01 | 0.404 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 3.944819e-01 | 0.404 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 3.965151e-01 | 0.402 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 3.965151e-01 | 0.402 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 3.996051e-01 | 0.398 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 4.042210e-01 | 0.393 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 4.057986e-01 | 0.392 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 4.057986e-01 | 0.392 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 4.057986e-01 | 0.392 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 4.096378e-01 | 0.388 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 4.096378e-01 | 0.388 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 4.096378e-01 | 0.388 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 4.096378e-01 | 0.388 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 4.125657e-01 | 0.385 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 4.144841e-01 | 0.382 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 4.213674e-01 | 0.375 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 4.217997e-01 | 0.375 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 4.217997e-01 | 0.375 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 4.218587e-01 | 0.375 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 4.218587e-01 | 0.375 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 4.218587e-01 | 0.375 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 4.218587e-01 | 0.375 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 4.218587e-01 | 0.375 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 4.218587e-01 | 0.375 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 4.293088e-01 | 0.367 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 4.320673e-01 | 0.364 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 4.321995e-01 | 0.364 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 4.321995e-01 | 0.364 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 4.321995e-01 | 0.364 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 4.365887e-01 | 0.360 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 4.387579e-01 | 0.358 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 4.393067e-01 | 0.357 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 4.393067e-01 | 0.357 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 4.422108e-01 | 0.354 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 4.437174e-01 | 0.353 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 4.437174e-01 | 0.353 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 4.437174e-01 | 0.353 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 4.437174e-01 | 0.353 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 4.439057e-01 | 0.353 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 4.439057e-01 | 0.353 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 4.439057e-01 | 0.353 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 4.439057e-01 | 0.353 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 4.439057e-01 | 0.353 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 4.439057e-01 | 0.353 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 4.447970e-01 | 0.352 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 4.522100e-01 | 0.345 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 4.522100e-01 | 0.345 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 4.522100e-01 | 0.345 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 4.522100e-01 | 0.345 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 4.522100e-01 | 0.345 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 4.522100e-01 | 0.345 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 4.522100e-01 | 0.345 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 4.522100e-01 | 0.345 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 4.522100e-01 | 0.345 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 4.522100e-01 | 0.345 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 4.522100e-01 | 0.345 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 4.522100e-01 | 0.345 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 4.522100e-01 | 0.345 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 4.522100e-01 | 0.345 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 4.557350e-01 | 0.341 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 4.567106e-01 | 0.340 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 4.567106e-01 | 0.340 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 4.567106e-01 | 0.340 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 4.607637e-01 | 0.337 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 4.656897e-01 | 0.332 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 4.656897e-01 | 0.332 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 4.705236e-01 | 0.327 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.766269e-01 | 0.322 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 4.766732e-01 | 0.322 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 4.766732e-01 | 0.322 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 4.766732e-01 | 0.322 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 4.766732e-01 | 0.322 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 4.766732e-01 | 0.322 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 4.766732e-01 | 0.322 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 4.766732e-01 | 0.322 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 4.766732e-01 | 0.322 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 4.804945e-01 | 0.318 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 4.832613e-01 | 0.316 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 4.835969e-01 | 0.316 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 4.835969e-01 | 0.316 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 4.835969e-01 | 0.316 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 4.835969e-01 | 0.316 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 4.835969e-01 | 0.316 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 4.835969e-01 | 0.316 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 4.871593e-01 | 0.312 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 4.871593e-01 | 0.312 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 4.894458e-01 | 0.310 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 4.910924e-01 | 0.309 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 4.933947e-01 | 0.307 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 4.949987e-01 | 0.305 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 5.041768e-01 | 0.297 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 5.045039e-01 | 0.297 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 5.045039e-01 | 0.297 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 5.045039e-01 | 0.297 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 5.045039e-01 | 0.297 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 5.045039e-01 | 0.297 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 5.045039e-01 | 0.297 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 5.045039e-01 | 0.297 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 5.045039e-01 | 0.297 | 0 | 0 |
| Interleukin-36 pathway | R-HSA-9014826 | 5.045039e-01 | 0.297 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 5.045039e-01 | 0.297 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 5.045039e-01 | 0.297 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 5.045039e-01 | 0.297 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 5.045039e-01 | 0.297 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 5.045039e-01 | 0.297 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 5.079555e-01 | 0.294 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 5.079555e-01 | 0.294 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 5.081179e-01 | 0.294 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 5.081179e-01 | 0.294 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 5.081179e-01 | 0.294 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 5.081179e-01 | 0.294 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 5.081179e-01 | 0.294 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 5.081563e-01 | 0.294 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 5.084092e-01 | 0.294 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 5.084092e-01 | 0.294 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 5.084092e-01 | 0.294 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 5.084092e-01 | 0.294 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 5.084092e-01 | 0.294 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 5.084092e-01 | 0.294 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 5.084092e-01 | 0.294 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 5.084092e-01 | 0.294 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 5.084492e-01 | 0.294 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 5.084492e-01 | 0.294 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 5.084492e-01 | 0.294 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 5.084492e-01 | 0.294 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 5.183348e-01 | 0.285 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 5.247288e-01 | 0.280 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 5.289772e-01 | 0.277 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 5.289772e-01 | 0.277 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 5.326594e-01 | 0.274 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 5.326594e-01 | 0.274 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 5.326594e-01 | 0.274 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 5.326594e-01 | 0.274 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 5.326594e-01 | 0.274 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 5.348959e-01 | 0.272 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 5.386206e-01 | 0.269 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 5.386206e-01 | 0.269 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 5.388581e-01 | 0.269 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 5.388581e-01 | 0.269 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 5.388581e-01 | 0.269 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 5.388581e-01 | 0.269 | 0 | 0 |
| Immune System | R-HSA-168256 | 5.394558e-01 | 0.268 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 5.412081e-01 | 0.267 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 5.428441e-01 | 0.265 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 5.445914e-01 | 0.264 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 5.445914e-01 | 0.264 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 5.445914e-01 | 0.264 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 5.445914e-01 | 0.264 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 5.472154e-01 | 0.262 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 5.492488e-01 | 0.260 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 5.492488e-01 | 0.260 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 5.492488e-01 | 0.260 | 0 | 0 |
| Plus-strand DNA synthesis | R-HSA-164525 | 5.518083e-01 | 0.258 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 5.518083e-01 | 0.258 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 5.518083e-01 | 0.258 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 5.518083e-01 | 0.258 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 5.518083e-01 | 0.258 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 5.518083e-01 | 0.258 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 5.518083e-01 | 0.258 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 5.518083e-01 | 0.258 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 5.518083e-01 | 0.258 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 5.518083e-01 | 0.258 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 5.518083e-01 | 0.258 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 5.518083e-01 | 0.258 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 5.518083e-01 | 0.258 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 5.561816e-01 | 0.255 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 5.561816e-01 | 0.255 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 5.561816e-01 | 0.255 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 5.574333e-01 | 0.254 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 5.679764e-01 | 0.246 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 5.679764e-01 | 0.246 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 5.679764e-01 | 0.246 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 5.679764e-01 | 0.246 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 5.679764e-01 | 0.246 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 5.680794e-01 | 0.246 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 5.684800e-01 | 0.245 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 5.690525e-01 | 0.245 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 5.690525e-01 | 0.245 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 5.690525e-01 | 0.245 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 5.690525e-01 | 0.245 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 5.789789e-01 | 0.237 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 5.797316e-01 | 0.237 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 5.797316e-01 | 0.237 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 5.800337e-01 | 0.237 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 5.830687e-01 | 0.234 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 5.830687e-01 | 0.234 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 5.878863e-01 | 0.231 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 5.883619e-01 | 0.230 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 5.883619e-01 | 0.230 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 5.945992e-01 | 0.226 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 5.945992e-01 | 0.226 | 0 | 0 |
| Uncoating of the HIV Virion | R-HSA-162585 | 5.945992e-01 | 0.226 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 5.945992e-01 | 0.226 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 5.945992e-01 | 0.226 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 5.945992e-01 | 0.226 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 5.945992e-01 | 0.226 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 5.945992e-01 | 0.226 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 5.945992e-01 | 0.226 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 5.945992e-01 | 0.226 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 5.957405e-01 | 0.225 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 5.957405e-01 | 0.225 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 5.957405e-01 | 0.225 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 5.967474e-01 | 0.224 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 5.974120e-01 | 0.224 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 6.010228e-01 | 0.221 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 6.010228e-01 | 0.221 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 6.071546e-01 | 0.217 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 6.133701e-01 | 0.212 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 6.187616e-01 | 0.208 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 6.221437e-01 | 0.206 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 6.221437e-01 | 0.206 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 6.221437e-01 | 0.206 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 6.221437e-01 | 0.206 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 6.221437e-01 | 0.206 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 6.221437e-01 | 0.206 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 6.221437e-01 | 0.206 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 6.222923e-01 | 0.206 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 6.222923e-01 | 0.206 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 6.222923e-01 | 0.206 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 6.254127e-01 | 0.204 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 6.333070e-01 | 0.198 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 6.333070e-01 | 0.198 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 6.333070e-01 | 0.198 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 6.333070e-01 | 0.198 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 6.333070e-01 | 0.198 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 6.333070e-01 | 0.198 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 6.333070e-01 | 0.198 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 6.333070e-01 | 0.198 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 6.333070e-01 | 0.198 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 6.333070e-01 | 0.198 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 6.333070e-01 | 0.198 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 6.333070e-01 | 0.198 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 6.333070e-01 | 0.198 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 6.341559e-01 | 0.198 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 6.354840e-01 | 0.197 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 6.427729e-01 | 0.192 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 6.427729e-01 | 0.192 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 6.435577e-01 | 0.191 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 6.471927e-01 | 0.189 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 6.471927e-01 | 0.189 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 6.471927e-01 | 0.189 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 6.471927e-01 | 0.189 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 6.471927e-01 | 0.189 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 6.602708e-01 | 0.180 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 6.607456e-01 | 0.180 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 6.621286e-01 | 0.179 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 6.624567e-01 | 0.179 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 6.624567e-01 | 0.179 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 6.624567e-01 | 0.179 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 6.625461e-01 | 0.179 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 6.637152e-01 | 0.178 | 0 | 0 |
| Reverse Transcription of HIV RNA | R-HSA-162589 | 6.683210e-01 | 0.175 | 0 | 0 |
| Minus-strand DNA synthesis | R-HSA-164516 | 6.683210e-01 | 0.175 | 0 | 0 |
| RSK activation | R-HSA-444257 | 6.683210e-01 | 0.175 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 6.683210e-01 | 0.175 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 6.683210e-01 | 0.175 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 6.683210e-01 | 0.175 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 6.683210e-01 | 0.175 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 6.683210e-01 | 0.175 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 6.683210e-01 | 0.175 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 6.683210e-01 | 0.175 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 6.683210e-01 | 0.175 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 6.683210e-01 | 0.175 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 6.683210e-01 | 0.175 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 6.683210e-01 | 0.175 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 6.683210e-01 | 0.175 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 6.709054e-01 | 0.173 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 6.709054e-01 | 0.173 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 6.709054e-01 | 0.173 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 6.709054e-01 | 0.173 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 6.756732e-01 | 0.170 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 6.762111e-01 | 0.170 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 6.768525e-01 | 0.170 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 6.768525e-01 | 0.170 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 6.777268e-01 | 0.169 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 6.790620e-01 | 0.168 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 6.813407e-01 | 0.167 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 6.813407e-01 | 0.167 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 6.863798e-01 | 0.163 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 6.892279e-01 | 0.162 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 6.914013e-01 | 0.160 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 6.928623e-01 | 0.159 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 6.928623e-01 | 0.159 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 6.928623e-01 | 0.159 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 6.932100e-01 | 0.159 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 6.932100e-01 | 0.159 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 6.933085e-01 | 0.159 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 6.933085e-01 | 0.159 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 6.933085e-01 | 0.159 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 6.933085e-01 | 0.159 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 6.933085e-01 | 0.159 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 6.994268e-01 | 0.155 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 6.994268e-01 | 0.155 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 6.999935e-01 | 0.155 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 6.999935e-01 | 0.155 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 6.999935e-01 | 0.155 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 6.999935e-01 | 0.155 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 6.999935e-01 | 0.155 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 6.999935e-01 | 0.155 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 6.999935e-01 | 0.155 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 6.999935e-01 | 0.155 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 6.999935e-01 | 0.155 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 6.999935e-01 | 0.155 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 6.999935e-01 | 0.155 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 7.081631e-01 | 0.150 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 7.082982e-01 | 0.150 | 0 | 0 |
| Disease | R-HSA-1643685 | 7.137251e-01 | 0.146 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 7.143092e-01 | 0.146 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 7.144358e-01 | 0.146 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 7.144358e-01 | 0.146 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 7.144358e-01 | 0.146 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 7.144358e-01 | 0.146 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 7.144358e-01 | 0.146 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 7.144358e-01 | 0.146 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 7.144358e-01 | 0.146 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 7.144358e-01 | 0.146 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 7.167213e-01 | 0.145 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 7.167213e-01 | 0.145 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 7.167213e-01 | 0.145 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 7.231611e-01 | 0.141 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 7.231611e-01 | 0.141 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 7.231611e-01 | 0.141 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 7.272194e-01 | 0.138 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 7.286432e-01 | 0.137 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 7.286432e-01 | 0.137 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 7.286432e-01 | 0.137 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 7.286432e-01 | 0.137 | 0 | 0 |
| Peptide hormone biosynthesis | R-HSA-209952 | 7.286432e-01 | 0.137 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 7.286432e-01 | 0.137 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 7.286432e-01 | 0.137 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 7.309192e-01 | 0.136 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 7.332337e-01 | 0.135 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 7.343268e-01 | 0.134 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 7.343268e-01 | 0.134 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 7.343268e-01 | 0.134 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 7.374538e-01 | 0.132 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 7.437930e-01 | 0.129 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 7.441415e-01 | 0.128 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 7.489770e-01 | 0.126 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 7.489770e-01 | 0.126 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 7.530247e-01 | 0.123 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 7.530247e-01 | 0.123 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 7.530247e-01 | 0.123 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 7.530247e-01 | 0.123 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 7.545586e-01 | 0.122 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 7.545586e-01 | 0.122 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 7.545586e-01 | 0.122 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 7.545586e-01 | 0.122 | 0 | 0 |
| Inorganic anion exchange by SLC26 transporters | R-HSA-427601 | 7.545586e-01 | 0.122 | 0 | 0 |
| Vitamin B1 (thiamin) metabolism | R-HSA-196819 | 7.545586e-01 | 0.122 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 7.545586e-01 | 0.122 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 7.545586e-01 | 0.122 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 7.545586e-01 | 0.122 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 7.545586e-01 | 0.122 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 7.639667e-01 | 0.117 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 7.697418e-01 | 0.114 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 7.705760e-01 | 0.113 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 7.780003e-01 | 0.109 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 7.780003e-01 | 0.109 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 7.780003e-01 | 0.109 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 7.780003e-01 | 0.109 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 7.780003e-01 | 0.109 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 7.780003e-01 | 0.109 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 7.780003e-01 | 0.109 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 7.780003e-01 | 0.109 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 7.782204e-01 | 0.109 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 7.782204e-01 | 0.109 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 7.782204e-01 | 0.109 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 7.782204e-01 | 0.109 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 7.834540e-01 | 0.106 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 7.870292e-01 | 0.104 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 7.870292e-01 | 0.104 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 7.890481e-01 | 0.103 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 7.899343e-01 | 0.102 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 7.903391e-01 | 0.102 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 7.908243e-01 | 0.102 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 7.908243e-01 | 0.102 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 7.908243e-01 | 0.102 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 7.917577e-01 | 0.101 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 7.988339e-01 | 0.098 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 7.992044e-01 | 0.097 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 7.992044e-01 | 0.097 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 7.992044e-01 | 0.097 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 7.992044e-01 | 0.097 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 7.992044e-01 | 0.097 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 7.992044e-01 | 0.097 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 7.992044e-01 | 0.097 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 7.992044e-01 | 0.097 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 7.992044e-01 | 0.097 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 7.992044e-01 | 0.097 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 7.992044e-01 | 0.097 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 8.004352e-01 | 0.097 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 8.024338e-01 | 0.096 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 8.024338e-01 | 0.096 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 8.024338e-01 | 0.096 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 8.035174e-01 | 0.095 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 8.035174e-01 | 0.095 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 8.037729e-01 | 0.095 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 8.045995e-01 | 0.094 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 8.045995e-01 | 0.094 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 8.045995e-01 | 0.094 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 8.045995e-01 | 0.094 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 8.115768e-01 | 0.091 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 8.167680e-01 | 0.088 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 8.168399e-01 | 0.088 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 8.168399e-01 | 0.088 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 8.168399e-01 | 0.088 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 8.168399e-01 | 0.088 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 8.168399e-01 | 0.088 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 8.168399e-01 | 0.088 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 8.168399e-01 | 0.088 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 8.168399e-01 | 0.088 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 8.168399e-01 | 0.088 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 8.168399e-01 | 0.088 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 8.168399e-01 | 0.088 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 8.168399e-01 | 0.088 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 8.183843e-01 | 0.087 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 8.183843e-01 | 0.087 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 8.183843e-01 | 0.087 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 8.183843e-01 | 0.087 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 8.183843e-01 | 0.087 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 8.183843e-01 | 0.087 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 8.183843e-01 | 0.087 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 8.183843e-01 | 0.087 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 8.183843e-01 | 0.087 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 8.204571e-01 | 0.086 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 8.205172e-01 | 0.086 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 8.205172e-01 | 0.086 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 8.240603e-01 | 0.084 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 8.282863e-01 | 0.082 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 8.294587e-01 | 0.081 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 8.294587e-01 | 0.081 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 8.302978e-01 | 0.081 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 8.302978e-01 | 0.081 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 8.302978e-01 | 0.081 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 8.302978e-01 | 0.081 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 8.321929e-01 | 0.080 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 8.357332e-01 | 0.078 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 8.357332e-01 | 0.078 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 8.357332e-01 | 0.078 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 8.357332e-01 | 0.078 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 8.357332e-01 | 0.078 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 8.357332e-01 | 0.078 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 8.357332e-01 | 0.078 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 8.357332e-01 | 0.078 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.357332e-01 | 0.078 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 8.357332e-01 | 0.078 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 8.357332e-01 | 0.078 | 0 | 0 |
| Ciprofloxacin ADME | R-HSA-9793528 | 8.357332e-01 | 0.078 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 8.357332e-01 | 0.078 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 8.357332e-01 | 0.078 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 8.373867e-01 | 0.077 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 8.379477e-01 | 0.077 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 8.428570e-01 | 0.074 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 8.428570e-01 | 0.074 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 8.494673e-01 | 0.071 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 8.514258e-01 | 0.070 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 8.514258e-01 | 0.070 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 8.514258e-01 | 0.070 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 8.514258e-01 | 0.070 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 8.514258e-01 | 0.070 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 8.514258e-01 | 0.070 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 8.514258e-01 | 0.070 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 8.514258e-01 | 0.070 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 8.514258e-01 | 0.070 | 0 | 0 |
| Transport and metabolism of PAPS | R-HSA-174362 | 8.514258e-01 | 0.070 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 8.514258e-01 | 0.070 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 8.514258e-01 | 0.070 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 8.514258e-01 | 0.070 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 8.514258e-01 | 0.070 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 8.545665e-01 | 0.068 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 8.550572e-01 | 0.068 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 8.591783e-01 | 0.066 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 8.602670e-01 | 0.065 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 8.656201e-01 | 0.063 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 8.656201e-01 | 0.063 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 8.656201e-01 | 0.063 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 8.656201e-01 | 0.063 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 8.656201e-01 | 0.063 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 8.656201e-01 | 0.063 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 8.656201e-01 | 0.063 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 8.656201e-01 | 0.063 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 8.656201e-01 | 0.063 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 8.656201e-01 | 0.063 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 8.656201e-01 | 0.063 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 8.656201e-01 | 0.063 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 8.656201e-01 | 0.063 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 8.701189e-01 | 0.060 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 8.756255e-01 | 0.058 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 8.756255e-01 | 0.058 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 8.756255e-01 | 0.058 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 8.756255e-01 | 0.058 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 8.769628e-01 | 0.057 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 8.769628e-01 | 0.057 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 8.779087e-01 | 0.057 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 8.784590e-01 | 0.056 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 8.784590e-01 | 0.056 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 8.784590e-01 | 0.056 | 0 | 0 |
| Heme assimilation | R-HSA-9927020 | 8.784590e-01 | 0.056 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 8.784590e-01 | 0.056 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 8.784590e-01 | 0.056 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 8.784590e-01 | 0.056 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 8.784590e-01 | 0.056 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 8.784590e-01 | 0.056 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 8.829193e-01 | 0.054 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 8.844645e-01 | 0.053 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 8.848913e-01 | 0.053 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 8.850662e-01 | 0.053 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 8.900720e-01 | 0.051 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 8.900720e-01 | 0.051 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 8.900720e-01 | 0.051 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 8.900720e-01 | 0.051 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 8.900720e-01 | 0.051 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 8.938391e-01 | 0.049 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 8.938391e-01 | 0.049 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 8.999044e-01 | 0.046 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 9.005760e-01 | 0.045 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 9.005760e-01 | 0.045 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 9.005760e-01 | 0.045 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.005760e-01 | 0.045 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 9.005760e-01 | 0.045 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 9.019855e-01 | 0.045 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.066485e-01 | 0.043 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.066485e-01 | 0.043 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.073048e-01 | 0.042 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.088122e-01 | 0.042 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.095451e-01 | 0.041 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 9.100769e-01 | 0.041 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 9.100769e-01 | 0.041 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 9.100769e-01 | 0.041 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.100769e-01 | 0.041 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.100769e-01 | 0.041 | 0 | 0 |
| Methionine salvage pathway | R-HSA-1237112 | 9.100769e-01 | 0.041 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 9.100769e-01 | 0.041 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 9.100769e-01 | 0.041 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.111588e-01 | 0.040 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.165556e-01 | 0.038 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.165556e-01 | 0.038 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.180273e-01 | 0.037 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 9.186704e-01 | 0.037 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 9.186704e-01 | 0.037 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.186704e-01 | 0.037 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.186704e-01 | 0.037 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.186704e-01 | 0.037 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 9.197439e-01 | 0.036 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 9.197439e-01 | 0.036 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 9.264431e-01 | 0.033 | 0 | 0 |
| Abacavir metabolism | R-HSA-2161541 | 9.264431e-01 | 0.033 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.264431e-01 | 0.033 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.272486e-01 | 0.033 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.285581e-01 | 0.032 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 9.290710e-01 | 0.032 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 9.290710e-01 | 0.032 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 9.290710e-01 | 0.032 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 9.290710e-01 | 0.032 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.296927e-01 | 0.032 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 9.334734e-01 | 0.030 | 0 | 0 |
| Androgen biosynthesis | R-HSA-193048 | 9.334734e-01 | 0.030 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 9.334734e-01 | 0.030 | 0 | 0 |
| Glucocorticoid biosynthesis | R-HSA-194002 | 9.334734e-01 | 0.030 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 9.334734e-01 | 0.030 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 9.346421e-01 | 0.029 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 9.397966e-01 | 0.027 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.397966e-01 | 0.027 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 9.398321e-01 | 0.027 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 9.398321e-01 | 0.027 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 9.398321e-01 | 0.027 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 9.398321e-01 | 0.027 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 9.398321e-01 | 0.027 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.398321e-01 | 0.027 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 9.398321e-01 | 0.027 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 9.398321e-01 | 0.027 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.408374e-01 | 0.026 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 9.419231e-01 | 0.026 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.428831e-01 | 0.026 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.448806e-01 | 0.025 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 9.455834e-01 | 0.024 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 9.455834e-01 | 0.024 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 9.455834e-01 | 0.024 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.455834e-01 | 0.024 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 9.455834e-01 | 0.024 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.480748e-01 | 0.023 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 9.507853e-01 | 0.022 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.507853e-01 | 0.022 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 9.507853e-01 | 0.022 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.530399e-01 | 0.021 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.554901e-01 | 0.020 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 9.554901e-01 | 0.020 | 0 | 0 |
| Defects in cobalamin (B12) metabolism | R-HSA-3296469 | 9.554901e-01 | 0.020 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.554901e-01 | 0.020 | 0 | 0 |
| Beta-oxidation of pristanoyl-CoA | R-HSA-389887 | 9.554901e-01 | 0.020 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.557261e-01 | 0.020 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.564883e-01 | 0.019 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 9.567988e-01 | 0.019 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 9.567988e-01 | 0.019 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.578484e-01 | 0.019 | 0 | 0 |
| Linoleic acid (LA) metabolism | R-HSA-2046105 | 9.597455e-01 | 0.018 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 9.597455e-01 | 0.018 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 9.597455e-01 | 0.018 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.608434e-01 | 0.017 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.608759e-01 | 0.017 | 0 | 0 |
| Cobalamin (Cbl) metabolism | R-HSA-9759218 | 9.635942e-01 | 0.016 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 9.635942e-01 | 0.016 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 9.635942e-01 | 0.016 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.635942e-01 | 0.016 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.635942e-01 | 0.016 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.635942e-01 | 0.016 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.663278e-01 | 0.015 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 9.664228e-01 | 0.015 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.664228e-01 | 0.015 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 9.670752e-01 | 0.015 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 9.670752e-01 | 0.015 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.697325e-01 | 0.013 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.700150e-01 | 0.013 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.700150e-01 | 0.013 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 9.702235e-01 | 0.013 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 9.702235e-01 | 0.013 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 9.702235e-01 | 0.013 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.726814e-01 | 0.012 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 9.730709e-01 | 0.012 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 9.730709e-01 | 0.012 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.730709e-01 | 0.012 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.739654e-01 | 0.011 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.756462e-01 | 0.011 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.760942e-01 | 0.011 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.767207e-01 | 0.010 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.767710e-01 | 0.010 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.786929e-01 | 0.009 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.787561e-01 | 0.009 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.800819e-01 | 0.009 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.809141e-01 | 0.008 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.815175e-01 | 0.008 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.819871e-01 | 0.008 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.819871e-01 | 0.008 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.837101e-01 | 0.007 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.837101e-01 | 0.007 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.843840e-01 | 0.007 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.843840e-01 | 0.007 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.844479e-01 | 0.007 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.848417e-01 | 0.007 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 9.852684e-01 | 0.006 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 9.852684e-01 | 0.006 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.852684e-01 | 0.006 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.852684e-01 | 0.006 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.854995e-01 | 0.006 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.855607e-01 | 0.006 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.861466e-01 | 0.006 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.866777e-01 | 0.006 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.867336e-01 | 0.006 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.879523e-01 | 0.005 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.890150e-01 | 0.005 | 0 | 0 |
| Diseases associated with N-glycosylation of proteins | R-HSA-3781860 | 9.901475e-01 | 0.004 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.905656e-01 | 0.004 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.907782e-01 | 0.004 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.907782e-01 | 0.004 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.910903e-01 | 0.004 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.922638e-01 | 0.003 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.927140e-01 | 0.003 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.930370e-01 | 0.003 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.934113e-01 | 0.003 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.935172e-01 | 0.003 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.939966e-01 | 0.003 | 0 | 0 |
| Synthesis of very long-chain fatty acyl-CoAs | R-HSA-75876 | 9.940419e-01 | 0.003 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.940631e-01 | 0.003 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.946122e-01 | 0.002 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.949291e-01 | 0.002 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.954503e-01 | 0.002 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.954503e-01 | 0.002 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.960161e-01 | 0.002 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.961342e-01 | 0.002 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.967364e-01 | 0.001 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.967424e-01 | 0.001 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.967424e-01 | 0.001 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.968158e-01 | 0.001 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.970544e-01 | 0.001 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.971228e-01 | 0.001 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.975426e-01 | 0.001 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.978222e-01 | 0.001 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.979350e-01 | 0.001 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.979674e-01 | 0.001 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.982194e-01 | 0.001 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 9.983033e-01 | 0.001 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.985217e-01 | 0.001 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.987067e-01 | 0.001 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.987471e-01 | 0.001 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.988513e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.989311e-01 | 0.000 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.989311e-01 | 0.000 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.990269e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.990718e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.992044e-01 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.993055e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.995193e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.995863e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.996447e-01 | 0.000 | 0 | 0 |
| Metal ion assimilation from the host | R-HSA-9638482 | 9.996447e-01 | 0.000 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.996447e-01 | 0.000 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.996718e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.996788e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.997626e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.998054e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.998246e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.998247e-01 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.998414e-01 | 0.000 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.998595e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.998791e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999042e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999292e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999424e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.999501e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999566e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999742e-01 | 0.000 | 0 | 0 |
| Scavenging of heme from plasma | R-HSA-2168880 | 9.999767e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999789e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999828e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999849e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.999861e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.999884e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999887e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999896e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999915e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999918e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999941e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999949e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999949e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999958e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999964e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999982e-01 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 9.999990e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.999993e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999994e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999995e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999998e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999998e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999998e-01 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 9.999998e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |